[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-02 Phase II clinical trials in progress,,"},{"Key":"Keywords","Value":"Breast cancer,Targeted therapy,Neratinib,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>L. C. Kennedy<\/b><sup>1<\/sup>, N. Unni<sup>2<\/sup>, A. B. Hanker<sup>2<\/sup>, C. L. Arteaga<sup>2<\/sup>; <br\/><sup>1<\/sup>Vanderbilt University Medical Center, Nashville, TN, <sup>2<\/sup>University of Texas Southwestern, Dallas, TX","CSlideId":"","ControlKey":"22e3a719-ef03-4ae4-88aa-2164a3c080fe","ControlNumber":"10584","DisclosureBlock":"<b>&nbsp;L. C. Kennedy, <\/b> <br><b>Hoffmann-La Roche<\/b> Grant\/Contract. <br><b>Daiichi Sankyo<\/b> Other, Advisory board. <br><b>Puma Biotechnology<\/b> Grant\/Contract. <br><b>N. Unni, <\/b> <br><b>Pfizer<\/b> Other, Advisory Board. <br><b>Biotheranostics<\/b> Other, Advisory Board. <br><b>A. B. Hanker, <\/b> <br><b>Eli Lilly<\/b> Grant\/Contract. <br><b>C. L. Arteaga, <\/b> <br><b>Astra Zeneca<\/b> Other, Advisory Board. <br><b>Daiichi Sankyo<\/b> Other, Advisory Board. <br><b>Lilly<\/b> Grant\/Contract. <br><b>Laekna Therapeutics<\/b> Other, Advisory board. <br><b>TAIHO Oncology<\/b> Other, Advisory Board. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Takeda<\/b> Grant\/Contract.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11638","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT271","PresenterBiography":null,"PresenterDisplayName":"Laura Kennedy, MD;PhD","PresenterKey":"6902e424-d3e0-4b0b-b148-5a1417b68299","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT271. Neoadjuvant targeted therapy in stage I-III HER2-mutant lobular breast cancer","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Neoadjuvant targeted therapy in stage I-III HER2-mutant lobular breast cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-03 Phase III clinical trials in progress,,"},{"Key":"Keywords","Value":"Cancer prevention,Cancer disparities,Cancer screening,Faith-based interventions,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Gillian Gresham<sup>1<\/sup>, Christie  Y.  Jeon<sup>1<\/sup>, <b>Dong Hee Kim<\/b><sup>1<\/sup>, Min Jung Sung<sup>1<\/sup>, Laurel  J.  Finster<sup>1<\/sup>, Marcio  A.  Diniz<sup>2<\/sup>, Michael Fine<sup>1<\/sup>, Zul Surani<sup>1<\/sup>, Alison  K.  Herrmann<sup>3<\/sup>, Jeong Yup Lee<sup>4<\/sup>, Robert W. Haile<sup>1<\/sup><br><br\/><sup>1<\/sup>Cedars-Sinai Medical Center, Los Angeles, CA,<sup>2<\/sup>Mount Sinai, New York, NY,<sup>3<\/sup>University of California, Los Angeles, Los Angeles, CA,<sup>4<\/sup>LA Onnuri Community Church, Los Angeles, CA","CSlideId":"","ControlKey":"88c47afe-c4b8-4f9c-8c42-756b5f7111a7","ControlNumber":"9563","DisclosureBlock":"&nbsp;<b>G. Gresham, <\/b> None..<br><b>C. Y. Jeon, <\/b> None..<br><b>D. Kim, <\/b> None..<br><b>M. Sung, <\/b> None..<br><b>L. J. Finster, <\/b> None..<br><b>M. A. Diniz, <\/b> None..<br><b>M. Fine, <\/b> None..<br><b>Z. Surani, <\/b> None..<br><b>A. K. Herrmann, <\/b> None..<br><b>J. Lee, <\/b> None..<br><b>R. W. Haile, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11639","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT272","PresenterBiography":null,"PresenterDisplayName":"Dong Hee Kim, MPH","PresenterKey":"2d482093-0fae-4506-91e7-241c02498228","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT272. A cluster randomized trial to evaluate a church-based navigation model to increase breast cancer screening in Korean women (Faith In Action!): Trial in progress","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A cluster randomized trial to evaluate a church-based navigation model to increase breast cancer screening in Korean women (Faith In Action!): Trial in progress","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-03 Phase III clinical trials in progress,,"},{"Key":"Keywords","Value":"Diagnosis,Breast cancer,Cancer therapy,Metastatic potential,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>K. A. Sepulveda<\/b><sup>1<\/sup>, A. Roark<sup>1<\/sup>, S. Dhamne<sup>1<\/sup>, C. Nagi<sup>1<\/sup>, I. Marin<sup>1<\/sup>, I. Tabish<sup>1<\/sup>, S. Nizzero<sup>2<\/sup>, M. Gachechiladze<sup>3<\/sup>, T. Appenzeller<sup>3<\/sup>, P. Oertle<sup>3<\/sup>, M. Loparic<sup>3<\/sup>, S. G. Hilsenbeck<sup>1<\/sup>, M. Plodinec<sup>3<\/sup>, A. Thompson<sup>1<\/sup>; <br\/><sup>1<\/sup>Baylor College of Medicine, Houston, TX, <sup>2<\/sup>ARTIDIS INC, Houston, TX, <sup>3<\/sup>ARTIDIS, AG, Basel, Switzerland","CSlideId":"","ControlKey":"36f3ab3b-fd72-4df2-b782-dc7316fa7fbc","ControlNumber":"10551","DisclosureBlock":"<b>&nbsp;K. A. Sepulveda, <\/b> <br><b>ARTIDIS, AG<\/b> Grant\/Contract, Travel. <br><b>A. Roark, <\/b> <br><b>ARTIDIS, AG<\/b> Grant\/Contract, Travel. <br><b>S. Dhamne, <\/b> <br><b>ARTIDIS, AG<\/b> Grant\/Contract, Travel. <br><b>C. Nagi, <\/b> <br><b>ARTIDIS, AG<\/b> Grant\/Contract, Travel. <br><b>I. Marin, <\/b> <br><b>ARTIDIS, AG<\/b> Grant\/Contract. <br><b>I. Tabish, <\/b> <br><b>ARTIDIS, AG<\/b> Grant\/Contract. <br><b>S. Nizzero, <\/b> <br><b>ARTIDIS, AG<\/b> Employment, Independent Contractor, Travel. <br><b>M. Gachechiladze, <\/b> <br><b>ARTIDIS, AG<\/b> Employment, Travel. <br><b>T. Appenzeller, <\/b> <br><b>ARTIDIS, AG<\/b> Employment, Stock, Stock Option, Other Business Ownership, Travel, Patent, Other Intellectual Property, Co-Founder. <br><b>P. Oertle, <\/b> <br><b>ARTIDIS, AG<\/b> Employment, Stock, Stock Option, Other Business Ownership, Travel, Patent, Other Intellectual Property, Co-founder. <br><b>M. Loparic, <\/b> <br><b>ARTIDIS, AG<\/b> Employment, Stock, Stock Option, Other Business Ownership, Travel, Patent, Other Intellectual Property, Co-founder. <br><b>S. G. Hilsenbeck, <\/b> <br><b>ARTIDIS, AG<\/b> Grant\/Contract, Travel. <br><b>M. Plodinec, <\/b> <br><b>ARTIDIS, AG<\/b> Employment, Stock, Stock Option, Other Business Ownership, Travel, Patent, Other Intellectual Property, Co-founder, board member, CEO. <br><b>A. Thompson, <\/b> <br><b>ARTIDIS, AG<\/b> Grant\/Contract, Travel. <br><b>Eli Lilly<\/b> Other, Employment, Wife.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11640","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT273","PresenterBiography":null,"PresenterDisplayName":"Karla Sepulveda, MD","PresenterKey":"4115afec-b115-4996-929f-17d9d18671f4","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT273. Unique multicenter trial design to investigate ARTIDIS nanomechanical generated measurements for early breast lesions (ANGEL)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Unique multicenter trial design to investigate ARTIDIS nanomechanical generated measurements for early breast lesions (ANGEL)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-02 Phase II clinical trials in progress,,"},{"Key":"Keywords","Value":"Immunotherapy,Immune checkpoint,T cell,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Park<\/b><sup>1<\/sup>, M.-H. Chen<sup>2<\/sup>, A. Dechaphunkul<sup>3<\/sup>, N. Ding<sup>4<\/sup>, X. Lin<sup>4<\/sup>, J. Zhang<sup>4<\/sup>, V. Li<sup>4<\/sup>, Q. Li<sup>5<\/sup>, Y. Ba<sup>6<\/sup>; <br\/><sup>1<\/sup>Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of, <sup>2<\/sup>Taipei Veterans General Hospital, Taipei, Taiwan, <sup>3<\/sup>Holistic Center for Cancer Study and Care, Prince of Songkla University, Songkhla, Thailand, <sup>4<\/sup>BeiGene (Shanghai) Co., Ltd., Shanghai, China, <sup>5<\/sup>BeiGene (Beijing) Co., Ltd., Beijing, China, <sup>6<\/sup>Peking Union Medical College Hospital, Beijing, China","CSlideId":"","ControlKey":"28e696d8-cfd7-4a24-ab3a-cba489d12fea","ControlNumber":"9939","DisclosureBlock":"<b>&nbsp;S. Park, <\/b> <br><b>ImmuneOncia Therapeutics Inc.<\/b> Grant\/Contract. <br><b>Incyte<\/b> Grant\/Contract. <br><b>Ono Pharma Korea Co., Ltd.<\/b> Grant\/Contract. <br><b>BeiGene Korea<\/b> Independent Contractor. <br><b>Pfizer Pharmaceuticals Korea Ltd.<\/b> Independent Contractor. <br><b>MSD Korea<\/b> Independent Contractor.<br><b>M. Chen, <\/b> None..<br><b>A. Dechaphunkul, <\/b> None.&nbsp;<br><b>N. Ding, <\/b> <br><b>BeiGene<\/b> Employment. <br><b>X. Lin, <\/b> <br><b>BeiGene<\/b> Employment, Stock, Stock Option. <br><b>J. Zhang, <\/b> <br><b>BeiGene<\/b> Employment, Stock, Stock Option. <br><b>V. Li, <\/b> <br><b>BeiGene<\/b> Employment, Stock, Stock Option, Travel. <br><b>Q. Li, <\/b> <br><b>BeiGene<\/b> Employment, Stock, Stock Option.<br><b>Y. Ba, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11641","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT274","PresenterBiography":"","PresenterDisplayName":"Kayla Hayes, BA","PresenterKey":"aa2be8be-745d-491a-8832-1ceb669bcfcd","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT274. BGB<b>&#8209;<\/b>A317<b>&#8209;<\/b>LBL<b>&#8209;<\/b>007<b>&#8209;<\/b>202:<b> <\/b>A<b> <\/b>phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL<b>&#8209;<\/b>007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced\/metastatic esophageal squamous cell carcinoma (ESCC)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"BGB<b>&#8209;<\/b>A317<b>&#8209;<\/b>LBL<b>&#8209;<\/b>007<b>&#8209;<\/b>202:<b> <\/b>A<b> <\/b>phase 2, randomized, active-controlled, open-label study to evaluate the efficacy and safety of LBL<b>&#8209;<\/b>007 (anti-LAG-3) in combination with tislelizumab (TIS; anti-PD-1) plus chemotherapy (chemo) as first-line (1L) treatment in patients with unresectable locally advanced\/metastatic esophageal squamous cell carcinoma (ESCC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-02 Phase II clinical trials in progress,,"},{"Key":"Keywords","Value":"Colorectal cancer,Ras,Polo-like kinase,Bevacizumab,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"H.-J. Lenz<sup>1<\/sup>, B. Kuritzky<sup>2<\/sup>, A. Thummala<sup>3<\/sup>, S. Kendall<sup>4<\/sup>, R. Patel<sup>5<\/sup>, S. R. Chandana<sup>6<\/sup>, A. H. Bent<sup>7<\/sup>, N. Sherman<sup>8<\/sup>, <b>R. A. Subramanian<\/b><sup>8<\/sup>, F. Kabbinavar<sup>8<\/sup>, J. R. Hecht<sup>9<\/sup>; <br\/><sup>1<\/sup>USC Norris Comprehensive Cancer Center, Los Angeles, CA, <sup>2<\/sup>Trihealth, Cincinnatti, OH, <sup>3<\/sup>Comprehensive Cancer Centers, Las Vegas, NV, <sup>4<\/sup>Utah Cancer Specialitst, Salt lake city, UT, <sup>5<\/sup>Comprehensive Blood and Cancer Center, Bakersfield, CA, <sup>6<\/sup>West Michigan Cancer and Hematology Center, Grand Rapids, MI, <sup>7<\/sup>MD Anderson Cancer Center, Houston, TX, <sup>8<\/sup>Cardiff Oncology, Inc., San Diego, CA, <sup>9<\/sup>UCLA Jonsson Comprehensive Cancer, Santa Monica, CA","CSlideId":"","ControlKey":"26b92374-3df9-49fb-80ae-f87893c49d3b","ControlNumber":"10722","DisclosureBlock":"<b>&nbsp;H. Lenz, <\/b> <br><b>Cardiff Oncology Inc<\/b> Independent Contractor.<br><b>B. Kuritzky, <\/b> None..<br><b>A. Thummala, <\/b> None..<br><b>S. Kendall, <\/b> None..<br><b>R. Patel, <\/b> None..<br><b>S. R. Chandana, <\/b> None..<br><b>A. H. Bent, <\/b> None.&nbsp;<br><b>N. Sherman, <\/b> <br><b>Cardiff Oncology<\/b> Employment, Stock Option. <br><b>R. A. Subramanian, <\/b> <br><b>Cardiff Oncology<\/b> Employment, Stock Option. <br><b>Gossamer Bio Inc<\/b> Employment. <br><b>Johnson & Johnson<\/b> Employment. <br><b>F. Kabbinavar, <\/b> <br><b>Cardiff Oncology Inc<\/b> Employment, Stock Option.<br><b>J. R. Hecht, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11642","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT275","PresenterBiography":null,"PresenterDisplayName":"Ramanand Subramanian","PresenterKey":"765d57d3-4b5d-44c9-a60d-abf819f892dc","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT275. A phase 2, randomized, open-label study of onvansertib in combination with standard-of-care (SoC) versus SoC alone for first-line treatment of RAS-mutant metastatic colorectal cancer (mCRC)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 2, randomized, open-label study of onvansertib in combination with standard-of-care (SoC) versus SoC alone for first-line treatment of RAS-mutant metastatic colorectal cancer (mCRC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-02 Phase II clinical trials in progress,,"},{"Key":"Keywords","Value":"Colorectal cancer,Immune checkpoint,MSS\/pMMR,LAG-3 blockade,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Heinz-Josef Lenz<\/b><sup>1<\/sup>, Ying Yuan<sup>2<\/sup>, Vivian Li<sup>3<\/sup>, Juan Zhang<sup>4<\/sup>, Lubna Jamal<sup>5<\/sup>, Xiao Lin<sup>3<\/sup>, Fuxiang Zhu<sup>6<\/sup>, John  H.  Strickler<sup>7<\/sup><br><br\/><sup>1<\/sup>University of Southern California\/Norris Comprehensive Cancer Center, Los Angeles, CA,<sup>2<\/sup>The Second Hospital, Zhejiang University School of Medicine, Hangzhou, China,<sup>3<\/sup>BeiGene (Shanghai) Co., Ltd., Shanghai, China,<sup>4<\/sup>BeiGene (Beijing) Co., Ltd., Beijing, China,<sup>5<\/sup>BeiGene USA, Inc., Cambridge, MA,<sup>6<\/sup>BeiGene (Shanghai) Co., Ltd, Shanghai, China,<sup>7<\/sup>Duke University, Durham, NC","CSlideId":"","ControlKey":"e8c4277c-e134-4870-a96c-1210c13beae6","ControlNumber":"9899","DisclosureBlock":"<b>&nbsp;H. Lenz, <\/b> <br><b>NCI Moonshot U2C<\/b> Grant\/Contract. <br><b>Merck KG<\/b> Independent Contractor. <br><b>Bayer<\/b> Independent Contractor. <br><b>Isofol<\/b> Independent Contractor. <br><b>Merck<\/b> Independent Contractor. <br><b>Oncocyte<\/b> Independent Contractor. <br><b>Invitae<\/b> Independent Contractor. <br><b>Affini-T<\/b> Independent Contractor. <br><b>3T Bioscience<\/b> Independent Contractor. <br><b>Replimune<\/b> Independent Contractor. <br><b>G1 Therapeutics<\/b> Independent Contractor. <br><b>Jazz Therapeutics<\/b> Independent Contractor. <br><b>Adagene<\/b> Independent Contractor. <br><b>Fulgent<\/b> Independent Contractor.<br><b>Y. Yuan, <\/b> None.&nbsp;<br><b>V. Li, <\/b> <br><b>BeiGene<\/b> Employment, Stock, Stock Option, Travel. <br><b>J. Zhang, <\/b> <br><b>BeiGene<\/b> Employment, Stock, Stock Option, Travel. <br><b>L. Jamal, <\/b> <br><b>BeiGene<\/b> Employment. <br><b>X. Lin, <\/b> <br><b>BeiGene<\/b> Employment, Stock, Stock Option. <br><b>F. Zhu, <\/b> <br><b>BeiGene<\/b> Employment. <br><b>J. H. Strickler, <\/b> <br><b>BeiGene<\/b> Independent Contractor, Grant\/Contract.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11643","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT276","PresenterBiography":"","PresenterDisplayName":"Kayla Hayes, BA","PresenterKey":"aa2be8be-745d-491a-8832-1ceb669bcfcd","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT276. Liberty-201: Maintenance fluoropyrimidine and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)\/mismatch repair proficient (pMMR) colorectal cancer (CRC)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Liberty-201: Maintenance fluoropyrimidine and bevacizumab with or without anti-lymphocyte activation gene-3 (LAG-3) antibody LBL-007 plus anti-programmed cell death protein-1 (PD-1) antibody tislelizumab (TIS) for patients (pts) with metastatic or unresectable microsatellite stable (MSS)\/mismatch repair proficient (pMMR) colorectal cancer (CRC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-02 Phase II clinical trials in progress,,"},{"Key":"Keywords","Value":"Lung cancer: non-small cell,,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>G. Blumenschein, Jr.<\/b><sup>1<\/sup>, B. Besse<sup>2<\/sup>, J. F. Gainor<sup>3<\/sup>, D. Huang<sup>4<\/sup>, S. Kao<sup>5<\/sup>, S.-H. Lee<sup>6<\/sup>, L. Paz-Ares<sup>7<\/sup>, X. Chen<sup>8<\/sup>, W. He<sup>9<\/sup>, S. Gururangan<sup>10<\/sup>, K. Zhang<sup>11<\/sup>, C. Zhou<sup>12<\/sup>; <br\/><sup>1<\/sup>The University of Texas M.D. Anderson Cancer Center, Houston, TX, <sup>2<\/sup>Université Paris-Saclay, Villejuif, France, <sup>3<\/sup>Massachusetts General Hospital, Boston, MA, <sup>4<\/sup>Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Centre for Cancer, Tianjin, China, <sup>5<\/sup>Chris O’Brien Lifehouse, Sydney, Australia, <sup>6<\/sup>Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, <sup>7<\/sup>Universidad Complutense, CiberOnc, CNIO and Hospital Universitario 12 de Octubre, Madrid, Spain, <sup>8<\/sup>BeiGene USA, Inc., Ridgefield Park, NJ, <sup>9<\/sup>BeiGene (Beijing) Co., Ltd., Beijing, China, <sup>10<\/sup>BeiGene USA, Inc, San Mateo, CA, <sup>11<\/sup>BeiGene USA, Inc., San Mateo, CA, <sup>12<\/sup>Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China","CSlideId":"","ControlKey":"efd0bb7b-d72b-47d0-b717-393628baf8a3","ControlNumber":"9946","DisclosureBlock":"<b>&nbsp;G. Blumenschein, <\/b> <br><b>Amgen; Bayer; Adaptimmune; Exelixis; Daiichi Sankyo; GlaxoSmithKline; Immatics; Immunocore; Incyte; Kite Pharma; Macrogenics; Torque; AstraZeneca; Bristol-Myer Squib; Celgene; Genentech; MedImmune; M<\/b> Grant\/Contract. <br><b>Abbvie; Adicet; Amgen; Ariad; Bayer; Clovis Oncology; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Instil Bio; Genentech; Genzyme; Gilead; Lilly; Janssen; MedImmune; Merck; Novartis; R<\/b> Independent Contractor. <br><b>Maverick Therapeutics<\/b> Other, Advisory Board. <br><b>Virogin Biotech<\/b> Stock, Stock Option, Other, Advisory Board. <br><b>Johnson & Johnson\/Janssen<\/b> Other, Immediate family member employed. <br><b>B. Besse, <\/b> <br><b>Astrazeneca; Beigene; Genmab A\/S; GlaxoSmithKline; Janssen; Ose Immunotherapeutics; Pharmamar; Roche-Genentech; Sanofi; Takeda<\/b> Grant\/Contract. <br><b>Abbvie; Biontech SE; BristolMyerSqibb; Chugai pharmaceutical; CureVac AG; Daiichi Sankyo; F. Hoffmann-La Roche Ltd; Pharmamar; Regeneron; Sanofi aventis; Turning Point Therapeutics<\/b> Independent Contractor, Consulting fees. <br><b>Abbvie; Eli Lilly; Ellipse pharma Ltd; F.Hoffmann-La Roche Ltd; Genmab; Immunocore; Janssen; MSD; Ose Immunotherapeutics; Owkin; Taiho oncology<\/b> Other, Expert testimony. <br><b>Abbvie; Biontech SE; BristolMyerSqibb; Chugai pharmaceutical; CureVac AG; Daiichi Sankyo; F. Hoffmann-La Roche Ltd; Pharmamar; Regeneron; Sanofi aventis; Turning Point Therapeutics<\/b> Other, Participation on a Data Safety Monitoring Board or Advisory Board.<br><b>J. F. Gainor, <\/b> None..<br><b>D. Huang, <\/b> None.&nbsp;<br><b>S. Kao, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events; Advisory board. <br><b>MSD; BMS; Roche; Pfizer; Takeda; Beigene<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Pfizer; MSD; BMS; Roche; Amgen; Beigene; Boeringher<\/b> Other, Participation on a Data Safety Monitoring Board or Advisory Board. <br><b>S. Lee, <\/b> <br><b>AstraZeneca; MSD; Lunit<\/b> Grant\/Contract. <br><b>Roche; Lilly; Janssen; Amgen; AstraZeneca; MSD; Pfizer; BMS\/Ono<\/b> Other, Consulting fees. <br><b>L. Paz-Ares, <\/b> <br><b>MSD; Bristol-Myers Squibb; Roche; AstraZeneca; Eli Lilly<\/b> Other, Speaker's Bureau. <br><b>MSD; Roche; AstraZeneca<\/b> Travel. <br><b>MSD; Bristol-Myers Squibb; Roche; AstraZeneca; Eli Lilly; Merck; Novartis; Amgen; Incyte; Takeda; Blueprint; Bayer; PharmaMar; Ipsen<\/b> Other, Consulting or advisory role. <br><b>X. Chen, <\/b> <br><b>BeiGene<\/b> Employment. <br><b>W. He, <\/b> <br><b>BeiGene<\/b> Employment. <br><b>S. Gururangan, <\/b> <br><b>BeiGene<\/b> Employment, Stock, Stock Option, Travel. <br><b>K. Zhang, <\/b> <br><b>BeiGene<\/b> Employment, Stock, Stock Option, Travel. <br><b>C. Zhou, <\/b> <br><b>Amoy Diagnostics; Boehringer Ingelheim; C-Stone; Hengrui; Innovent Biologics; Lilly China; LUYE Pharma; MSD; Qilu; Roche; Sanofi; TopAlliance Biosciences Inc<\/b> Other, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. <br><b>Hengrui; Innovent Biologics; Qilu; TopAlliance Biosciences Inc<\/b> Other, Participation on a Data Safety Monitoring Board or Advisory Board.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11644","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT277","PresenterBiography":"","PresenterDisplayName":"Kayla Hayes, BA","PresenterKey":"aa2be8be-745d-491a-8832-1ceb669bcfcd","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT277. BGB-LC-201 (NCT05635708): A phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +\/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC)<b><\/b>","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"BGB-LC-201 (NCT05635708): A phase 2, open-label, multi-arm study of tislelizumab (TIS; anti-PD-1) in combination with investigational agents +\/- chemotherapy as first-line treatment for patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC)<b><\/b>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-02 Phase II clinical trials in progress,,"},{"Key":"Keywords","Value":"Lung cancer,Lung transplantation,Double lung transplantation,BOLT,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Y. Chae, <b>L.-Y. Chung<\/b>, R. Tomic, A. Bharat; <br\/>Northwestern Univ. Feinberg School of Medicine, Chicago, IL","CSlideId":"","ControlKey":"3f6a7ab9-b8e6-4203-9689-6fcb2fd6354e","ControlNumber":"10486","DisclosureBlock":"<b>&nbsp;Y. Chae, <\/b> <br><b>Abbvie<\/b> Grant\/Contract. <br><b>BMS<\/b> Grant\/Contract. <br><b>Biodesix<\/b> Grant\/Contract. <br><b>Freenome<\/b> Grant\/Contract. <br><b>Predicine<\/b> Grant\/Contract. <br><b>Roche\/Genentech<\/b> Other, Honoraria\/Advisory Boards. <br><b>AstraZeneca<\/b> Other, Honoraria\/Advisory Boards. <br><b>Foundation Medicine<\/b> Other, Honoraria\/Advisory Boards. <br><b>Neogenomics<\/b> Other, Honoraria\/Advisory Boards. <br><b>Guardant Health<\/b> Other, Honoraria\/Advisory Boards. <br><b>Boehringher Ingelheim<\/b> Other, Honoraria\/Advisory Boards. <br><b>Biodesix<\/b> Other, Honoraria\/Advisory Boards. <br><b>Immuneoncia<\/b> Other, Honoraria\/Advisory Boards. <br><b>Lilly Oncology<\/b> Other, Honoraria\/Advisory Boards. <br><b>Merck<\/b> Other, Honoraria\/Advisory Boards. <br><b>Takeda<\/b> Other, Honoraria\/Advisory Boards. <br><b>Lunit<\/b> Other, Honoraria\/Advisory Boards. <br><b>Jazz Pharmaceutical<\/b> Other, Honoraria\/Advisory Boards. <br><b>Tempus<\/b> Other, Honoraria\/Advisory Boards. <br><b>BMS<\/b> Other, Honoraria\/Advisory Boards.<br><b>L. Chung, <\/b> None..<br><b>R. Tomic, <\/b> None..<br><b>A. Bharat, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11645","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT278","PresenterBiography":null,"PresenterDisplayName":"Liam Il-Young Chung","PresenterKey":"266b7c9c-6ab6-4a12-9143-2cd0464e870c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT278. [DREAM] Double lung transplant registry aimed for lung-limited malignancies - a prospective registry study for medically refractory cancers","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"[DREAM] Double lung transplant registry aimed for lung-limited malignancies - a prospective registry study for medically refractory cancers","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-02 Phase II clinical trials in progress,,"},{"Key":"Keywords","Value":"Lung cancer: small cell,Neuroendocrine tumors,T cell engager,Targeted therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"V. Gambardella<sup>1<\/sup>, A. Greystoke<sup>2<\/sup>, M. Reck<sup>3<\/sup>, M. Liu<sup>4<\/sup>, <b>M. Mueller<\/b><sup>5<\/sup>, U. Duenzinger<sup>5<\/sup>, E. B. Bergsland<sup>6<\/sup>, T. Owonikoko<sup>7<\/sup>; <br\/><sup>1<\/sup>Department of Medical Oncology, Hospital Clínico Universitario de Valencia, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain, <sup>2<\/sup>Northern Centre for Cancer, Freeman Hospital, Newcastle Hospital Trust, Newcastle-upon-Tyne, United Kingdom, <sup>3<\/sup>Department of Thoracic Oncology, Airway Research Center North (ARCN) Member of the German Center for Lung Research (DZL), LungenClinic, Großhansdorf, Germany, <sup>4<\/sup>Boehringer Ingelheim (China) Investment Co. Ltd, Biostatistics and Data Sciences, Shanghai, China, <sup>5<\/sup>Boehringer Ingelheim International GmbH, Ingelheim, Germany, <sup>6<\/sup>Department of Medicine, University of California, San Francisco, CA, <sup>7<\/sup>UPMC Hillman Cancer Center, Division of Hematology\/Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA","CSlideId":"","ControlKey":"868e31bb-7d55-42be-83c4-fab847d11d7e","ControlNumber":"10489","DisclosureBlock":"<b>&nbsp;V. Gambardella, <\/b> <br><b>ESMO GI June 2023<\/b> Other, Payment\/honoraria. <br><b>Boehringer Ingelheim<\/b> Other, Support for attending meetings\/travel\u000d\u000aParticipation on a Data Safety Monitoring Board\/Advisory Board. <br><b>A. Greystoke, <\/b> <br><b>AstraZeneca<\/b> Other, Consultancy and Speaker Fees\u000d\u000aResearch Funding. <br><b>Amgen<\/b> Other, Consultancy and Speaker Fees. <br><b>Boehringer-Ingelheim<\/b> Other, Consultancy and Speaker Fees. <br><b>Bristol-Myers Squibb<\/b> Other, Consultancy and Speaker Fees. <br><b>Janssen\/ J and J<\/b> Other, Consultancy and Speaker Fees. <br><b>MSD<\/b> Other, Consultancy and Speaker Fees. <br><b>Novartis<\/b> Other, Consultancy and Speaker Fees. <br><b>Pfizer<\/b> Other, Consultancy and Speaker Fees. <br><b>Lilly<\/b> Other, Consultancy and Speaker Fees. <br><b>Takeda<\/b> Other, Consultancy and Speaker Fees. <br><b>Guardant<\/b> Other, Consultancy and Speaker Fees. <br><b>Roche<\/b> Other, Consultancy and Speaker Fees. <br><b>M. Reck, <\/b> <br><b>Amgen<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>AstraZeneca<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>Beigene<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>Boehringer-Ingelheim<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>BMS<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>Lilly<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>Merck<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>MSD<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>Mirati<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>Novartis<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>GSK<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>Pfizer<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>Roche<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>Regeneron<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>Sanofi<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel\u000d\u000aParticipation on a Data Safety Monitoring Board\/Advisory Board. <br><b>Daiichi-Sankyo<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel\u000d\u000aParticipation on a Data Safety Monitoring Board\/Advisory Board. <br><b>Janssen<\/b> Other, Consulting Fees\u000d\u000aPayment\/Honoraria\u000d\u000aSupport for Attending Meetings\/Travel. <br><b>M. Liu, <\/b> <br><b>Boehringer Ingelheim<\/b> Employment. <br><b>M. Mueller, <\/b> <br><b>Boehringer Ingelheim<\/b> Employment. <br><b>U. Duenzinger, <\/b> <br><b>Boehringer Ingelheim<\/b> Employment. <br><b>E. B. Bergsland, <\/b> <br><b>Boehringer Ingelheim<\/b> Other, Support for Medical Writing\u000d\u000aParticipation on a Data Safety Monitoring Board\/Advisory Board.<br><b>T. Owonikoko, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11646","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT279","PresenterBiography":null,"PresenterDisplayName":"Martha Mueller, Unknown","PresenterKey":"ebf50692-5163-498b-9b41-21ebeb146cd9","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT279. Dareon<sup>TM<\/sup>-5: An open-label phase 2 trial of BI 764532, a DLL3-targeting T-cell engager, in patients (pts) with relapsed\/refractory small cell lung cancer or other neuroendocrine carcinomas","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Dareon<sup>TM<\/sup>-5: An open-label phase 2 trial of BI 764532, a DLL3-targeting T-cell engager, in patients (pts) with relapsed\/refractory small cell lung cancer or other neuroendocrine carcinomas","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-03 Phase III clinical trials in progress,,"},{"Key":"Keywords","Value":"NSCLC,Epidermal growth factor receptor (EGFR),Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI),Furmonertinib,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. Spira<\/b><sup>1<\/sup>, B. Cho<sup>2<\/sup>, E. Felip<sup>3<\/sup>, E. Garon<sup>4<\/sup>, K. Goto<sup>5<\/sup>, M. L. Johnson<sup>6<\/sup>, N. B. Leighl<sup>7<\/sup>, A. Passaro<sup>8<\/sup>, D. Planchard<sup>9<\/sup>, S. Popat<sup>10<\/sup>, J. Yang<sup>11<\/sup>, X. Lu<sup>12<\/sup>, Y. Jiang<sup>12<\/sup>, J. Huang<sup>13<\/sup>, M. Lam<sup>13<\/sup>, M. Kowanetz<sup>13<\/sup>, S. Wang<sup>13<\/sup>, J. Le<sup>13<\/sup>, J. Hsu<sup>13<\/sup>, C. Zhou<sup>14<\/sup>; <br\/><sup>1<\/sup>Virginia Cancer Specialists Research Institute and Next Oncology, Fairfax, VA, <sup>2<\/sup>Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of, <sup>3<\/sup>Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain, <sup>4<\/sup>Department of Medicine, Division of Hematology\/Oncology, UCLA, Los Angeles, CA, <sup>5<\/sup>National Cancer Center Hospital East, Kashiwa, Japan, <sup>6<\/sup>The Sarah Cannon Research Institute, Nashville, TN, <sup>7<\/sup>Cancer Research Unit, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada, <sup>8<\/sup>Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy, <sup>9<\/sup>Gustave Roussy, Department of Medical Oncology, Villejuif, France, <sup>10<\/sup>The Royal Marsden NHS Foundation Trust, London and Sutton, United Kingdom, <sup>11<\/sup>National Taiwan University Hospital, Taipei, Taiwan, <sup>12<\/sup>Allist Pharmaceuticals, Shanghai, China, <sup>13<\/sup>Arrivent Biopharma, Inc., Burlingame, CA, <sup>14<\/sup>Department of Medical Oncology, Shanghai Pulmonary Hospital, Shanghai, China","CSlideId":"","ControlKey":"96b3f460-087b-4ed2-999e-e5b8962ef4c4","ControlNumber":"10437","DisclosureBlock":"<b>&nbsp;A. Spira, <\/b> <br><b>Array Biopharma<\/b> Other, Consult. <br><b>Incyte<\/b> Other, Consult. <br><b>Amgen<\/b> Other, Consult. <br><b>Novartis<\/b> Other, Consult. <br><b>AstraZeneca Medimmune<\/b> Other, Consult. <br><b>Mirati Therapeutics<\/b> Other, Consult. <br><b>Gritstone Bio<\/b> Other, Consult. <br><b>Jazz Pharmaceuticals<\/b> Other, Consult. <br><b>Merck<\/b> Other, Consult. <br><b>BMS<\/b> Other, Consult. <br><b>Takeda<\/b> Other, Consult. <br><b>Jannsen Research and Development<\/b> Other, Consult. <br><b>Mersana<\/b> Other, Consult. <br><b>Blueprint Medicines<\/b> Other, Consult. <br><b>Daiichi Sankyo\/AstraZeneca<\/b> Other, Consult. <br><b>Regeneron<\/b> Other, Consult. <br><b>Lilly<\/b> Stock, Other, Consult. <br><b>Black Diamond Therapeutics<\/b> Other, Consult. <br><b>Sanofi<\/b> Other, Consult. <br><b>Roche<\/b> Grant\/Contract. <br><b>B. Cho, <\/b> <br><b>AstraZeneca<\/b> Other, Consult. <br><b>Boehringer Ingelheim<\/b> Other, Consult. <br><b>Roche<\/b> Other, Consult. <br><b>BMS<\/b> Other, Consult. <br><b>Yuhan<\/b> Other, Consult. <br><b>Pfizer<\/b> Other, Consult. <br><b>Janssen<\/b> Other, Consult. <br><b>Takeda<\/b> Other, Consult. <br><b>MSD<\/b> Other, Consult. <br><b>Ono Pharmaceutical<\/b> Other, Consult. <br><b>Lilly<\/b> Other, Consult. <br><b>Medpacto<\/b> Other, Consult. <br><b>Blueprint Medicines<\/b> Other, Consult. <br><b>Cyrus Therapeutics<\/b> Other, Consult. <br><b>Guardant Health<\/b> Other, Consult. <br><b>Novartis<\/b> Other, Consult. <br><b>CJ Bioscience<\/b> Other, Consult. <br><b>Abion<\/b> Other, Consult. <br><b>BeiGene<\/b> Other, Consult. <br><b>CureLogen<\/b> Other, Consult. <br><b>E. Felip, <\/b> <br><b>Abbvie<\/b> Other, Consult. <br><b>Amgen<\/b> Other, Consult. <br><b>AstraZeneca<\/b> Other, Consult. <br><b>Bayer<\/b> Other, Consult. <br><b>Boehreinger Ingelheim<\/b> Other, Consult. <br><b>BMS<\/b> Other, Consult. <br><b>Lilly<\/b> Other, Consult. <br><b>Roche<\/b> Other, Consult. <br><b>Gilead Sciences<\/b> Other, Consult. <br><b>GlaxoSmithKline<\/b> Other, Consult. <br><b>Janssen<\/b> Other, Consult. <br><b>Merck Serono<\/b> Other, Consult. <br><b>Merck Sharp & Dohme<\/b> Other, Consult. <br><b>Novartis<\/b> Other, Consult. <br><b>Peptomyc<\/b> Other, Consult. <br><b>Pfizer<\/b> Other, Consult. <br><b>Regeneron<\/b> Other, Consult. <br><b>Sanofi<\/b> Other, Consult. <br><b>Takeda<\/b> Other, Consult. <br><b>Turning Point Therapeutics<\/b> Other, Consult. <br><b>E. Garon, <\/b> <br><b>Novartis<\/b> Other, Consult. <br><b>GlaxoSmithKline<\/b> Other, Consult. <br><b>Merck<\/b> Other, Consult. <br><b>Boehringer Ingelheim<\/b> Other, Consult. <br><b>Shionogi<\/b> Other, Consult. <br><b>Eisai<\/b> Other, Consult. <br><b>ABL Bio<\/b> Other, Consult. <br><b>Xilio Therapeutics<\/b> Other, Consult. <br><b>Natera<\/b> Other, Consult. <br><b>Sanofi\/Regeneron<\/b> Other, Consult. <br><b>Lilly<\/b> Other, Consult. <br><b>Personalis<\/b> Other, Consult. <br><b>Gilead Sciences<\/b> Other, Consult. <br><b>AstraZeneca<\/b> Other, Consult. <br><b>Abbvie\/Abbott<\/b> Other, Consult. <br><b>Arcus Biosciences<\/b> Other, Consult. <br><b>Seagen<\/b> Other, Consult. <br><b>Summit Therapeutics<\/b> Other, Consult. <br><b>Novartis<\/b> Travel. <br><b>A2 Biotherapeutics<\/b> Travel. <br><b>K. Goto, <\/b> <br><b>Bayer<\/b> Other, Consult. <br><b>Lilly Japan<\/b> Other, Consult. <br><b>Amgen<\/b> Other, Consult. <br><b>Medpace<\/b> Other, Consult. <br><b>Janssen<\/b> Other, Consult. <br><b>Amoy Diagonish<\/b> Other, Honoraria. <br><b>AstraZeneca Japan<\/b> Other, Honoraria. <br><b>Bayer<\/b> Other, Honoraria. <br><b>Boehringer Ingelheim<\/b> Other, Honoraria. <br><b>BMS<\/b> Other, Honoraria. <br><b>Chugai Pharma<\/b> Other, Honoraria. <br><b>Daiichi Sankyo<\/b> Other, Honoraria. <br><b>Eisai<\/b> Other, Honoraria. <br><b>Life Therapeutics<\/b> Other, Honoraria. <br><b>Medpace<\/b> Other, Honoraria. <br><b>Merck<\/b> Other, Honoraria. <br><b>Merck<\/b> Other, Honoraria. <br><b>Novartis<\/b> Other, Honoraria. <br><b>Ono Pharmaceutical<\/b> Other, Honoraria. <br><b>Otsuka<\/b> Other, Honoraria. <br><b>M. L. Johnson, <\/b> <br><b>Genentech\/Roche<\/b> Other, Consult. <br><b>AstraZeneca<\/b> Other, Consult. <br><b>Calithera Biosciences<\/b> Other, Consult. <br><b>Merck<\/b> Other, Consult. <br><b>Sanofi<\/b> Other, Consult. <br><b>Mirati Therapeutics<\/b> Other, Consult. <br><b>Ribon Therapeutics<\/b> Other, Consult. <br><b>Abbvie<\/b> Other, Consult. <br><b>GlaxoSmithKline<\/b> Other, Consult. <br><b>Gritstone Bio<\/b> Other, Consult. <br><b>Janssen Oncology<\/b> Other, Consult. <br><b>Lilly<\/b> Other, Consult. <br><b>Amgen<\/b> Other, Consult. <br><b>Daiichi Sankyo<\/b> Other, Consult. <br><b>Axelia Oncology<\/b> Other, Consult. <br><b>Black Diamond Therapeutics<\/b> Other, Consult. <br><b>CytomX Therapeutics<\/b> Other, Consult. <br><b>EcoR1 Capital<\/b> Other, Consult. <br><b>Editas Medicine<\/b> Other, Consult. <br><b>Genmab<\/b> Other, Consult. <br><b>N. B. Leighl, <\/b> <br><b>Roche Canada<\/b> Grant\/Contract. <br><b>Guardant Health<\/b> Grant\/Contract. <br><b>MSD<\/b> Grant\/Contract. <br><b>EMD Serono<\/b> Grant\/Contract. <br><b>AstraZeneca Canada<\/b> Grant\/Contract. <br><b>Takeda<\/b> Grant\/Contract. <br><b>Amgen<\/b> Grant\/Contract. <br><b>Bayer<\/b> Grant\/Contract. <br><b>A. Passaro, <\/b> <br><b>Roche\/Genentech<\/b> Other, Consult. <br><b>BMS<\/b> Other, Consult. <br><b>AstraZeneca<\/b> Other, Consult. <br><b>MSD Oncology<\/b> Other, Consult. <br><b>Pfizer<\/b> Other, Consult. <br><b>Boehringer Ingelheim<\/b> Other, Consult. <br><b>Johnson & Johnson\/Janssen<\/b> Other, Consult. <br><b>Novartis<\/b> Consult. <br><b>Daiichi Sankyo Europe GmbH<\/b> Other, Consult. <br><b>Bayer<\/b> Other, Consult. <br><b>D. Planchard, <\/b> <br><b>BMS<\/b> Other, Consult. <br><b>Celgene<\/b> Other, Consult. <br><b>Novartis<\/b> Other, Consult. <br><b>Pfizer<\/b> Other, Consult. <br><b>Novartis<\/b> Other, Consult. <br><b>Prime Oncology<\/b> Other, Consult. <br><b>PeerVoice<\/b> Other, Consult. <br><b>Roche<\/b> Other, Consult. <br><b>Samsung<\/b> Other, Consult. <br><b>Sanofi<\/b> Other, Consult. <br><b>Janssen<\/b> Other, Consult. <br><b>Abbvie<\/b> Other, Consult. <br><b>Daiichi Sankyo<\/b> Other, Consult. <br><b>AstraZeneca<\/b> Other, Consult. <br><b>Lilly<\/b> Other, Consult. <br><b>Merck<\/b> Other, Consult. <br><b>S. Popat, <\/b> <br><b>Boehringer Ingelheim<\/b> Other, Consult. <br><b>Roche<\/b> Other, Consult. <br><b>Novartis<\/b> Other, Consult. <br><b>Pfizer<\/b> Other, Consult. <br><b>AstraZeneca<\/b> Other, Consult. <br><b>BMS<\/b> Other, Consult. <br><b>MSD<\/b> Other, Consult. <br><b>Guardant Health<\/b> Other, Consult. <br><b>Takeda<\/b> Other, Consult. <br><b>Incyte<\/b> Other, Consult. <br><b>Bayer<\/b> Other, Consult. <br><b>Blueprint Medicines<\/b> Other, Consult. <br><b>Daiichi Sankyo<\/b> Other, Consult. <br><b>Janssen<\/b> Other, Consult. <br><b>GlaxoSmithKline<\/b> Other, Consult. <br><b>BeiGene<\/b> Other, Consult. <br><b>Lilly<\/b> Other, Consult. <br><b>Merck KGaA<\/b> Other, Consult. <br><b>Amgen<\/b> Other, Consult. <br><b>Pfizer<\/b> Other, Consult.<br><b>J. Yang, <\/b> None.&nbsp;<br><b>X. Lu, <\/b> <br><b>Allist Pharmaceuticals<\/b> Employment. <br><b>Y. Jiang, <\/b> <br><b>Allist Pharmaceuticals<\/b> Employment. <br><b>J. Huang, <\/b> <br><b>ArriVent Biopharma<\/b> Employment, Stock Option. <br><b>Pfizer<\/b> Stock. <br><b>M. Lam, <\/b> <br><b>Arrivent Biopharma<\/b> Employment, Stock Option. <br><b>M. Kowanetz, <\/b> <br><b>Arrivent Biopharma<\/b> Employment, Stock. <br><b>S. Wang, <\/b> <br><b>Arrivent Biopharma<\/b> Employment, Stock Option. <br><b>J. Le, <\/b> <br><b>ArriVent Biopharma<\/b> Employment. <br><b>Ascendis Pharma<\/b> Employment, Stock Option. <br><b>J. Hsu, <\/b> <br><b>Arrivent Biopharma<\/b> Employment, Stock Option. <br><b>C. Zhou, <\/b> <br><b>Innovent Biologics<\/b> Other, Consult. <br><b>QiLu Pharmaceutical<\/b> Other, Consult. <br><b>TopAlliance Biosciences<\/b> Other, Consult. <br><b>Hengrui Biosciences<\/b> Other, Consult. <br><b>Sanofi<\/b> Other, Honoraria. <br><b>Roche<\/b> Other, Honoraria. <br><b>C-Stone LUYE Pharma<\/b> Other, Honoraria. <br><b>Amoy Diagnosis<\/b> Other, Honoraria. <br><b>Anheart Therapeutics<\/b> Other, Honoraria. <br><b>Lilly<\/b> Other, Honoraria. <br><b>Boehringer Ingelheim<\/b> Other, Honoraria. <br><b>Merck<\/b> Other, Honoraria.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11647","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"10","PosterboardNumber":"10","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT280","PresenterBiography":null,"PresenterDisplayName":"Alex Spira, MD, PhD","PresenterKey":"03c25b24-88ed-4238-bc60-c007e35c3309","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT280. FURVENT, Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"FURVENT, Phase 3 trial testing furmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertions (FURMO-004)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-03 Phase III clinical trials in progress,,"},{"Key":"Keywords","Value":"Pembrolizumab,Adjuvant,Neoantigens,Personalized medicine,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. D. Spicer<\/b><sup>1<\/sup>, S. M. Nair<sup>2<\/sup>, A. Khattak<sup>3<\/sup>, J. M. Lee<sup>4<\/sup>, M. Brown<sup>5<\/sup>, R. S. Meehan<sup>5<\/sup>, N. Shariati<sup>6<\/sup>, X. Deng<sup>6<\/sup>, A. Samkari<sup>6<\/sup>, J. E. Chaft<sup>7<\/sup>; <br\/><sup>1<\/sup>McGill University Montreal, Montreal, QC, Canada, <sup>2<\/sup>Mid Florida Hematology and Oncology Center, Orange City, FL, <sup>3<\/sup>One Clinical Research and Edith Cowan University, Perth, WA, Australia, <sup>4<\/sup>Division of Thoracic Surgery, University of California, Los Angeles, Los Angeles, CA, <sup>5<\/sup>Moderna, Inc., Cambridge, MA, <sup>6<\/sup>Merck & Co., Inc., Rahway, NJ, <sup>7<\/sup>Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY","CSlideId":"","ControlKey":"848f34b6-508e-4acf-9a00-f33ca7df108b","ControlNumber":"10655","DisclosureBlock":"<b>&nbsp;J. D. Spicer, <\/b> <br><b>AstraZeneca, Bristol-Myers Squibb, Chemocentryx, Eisai Inc., F. Hoffmann-La Roche, Protalix Biotherapeutics, Regeneron Pharmaceuticals<\/b> Other, Advisory board. <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Advisory board. <br><b>CLS Therapeutics, F. Hoffmann-La Roche, Protalix Biotherapeutics, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Research grants to institute. <br><b>Regeneron Pharmaceuticals<\/b> Other, Consultancy. <br><b>S. M. Nair, <\/b> <br><b>AstraZeneca, Bristol Myers Squibb and Exact Science<\/b> Other, Study funding. <br><b>Moderna, Inc., Cambridge, MA, USA<\/b> Other, Study funding to institution. <br><b>A. Khattak, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Honoraria. <br><b>J. M. Lee, <\/b> <br><b>AstraZeneca, Bristol Myers Squibb, Foundation Medicine Institute, Genentech, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Novartis, Regeneron Pharmaceuticals, Roche<\/b> Other, Advisory Board\/Consultant. <br><b>Bristol Myers Squibb, Genentech, Novartis, Roche.<\/b> Other, Research support. <br><b>Genentech, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Novartis, Roche.<\/b> Other, Steering Committee. <br><b>AstraZeneca, Bristol Myers Squibb, Genentech, Roche<\/b> Other, Speaker’s Bureau. <br><b>UCLA<\/b> Other, Patents. <br><b>M. Brown, <\/b> <br><b>Moderna, Inc.<\/b> Employment, Stock. <br><b>R. S. Meehan, <\/b> <br><b>Moderna, Inc.<\/b> Employment, Stock. <br><b>N. Shariati, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>X. Deng, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA.<\/b> Stock. <br><b>A. Samkari, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA.<\/b> Stock. <br><b>J. E. Chaft, <\/b> <br><b>Arcus Biosciences, AstraZeneca, Bristol Myers Squibb, Janssen, Guardant Health, Regeneron, and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Consultancy. <br><b>NIH<\/b> Other, Research grant. <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Funding to the institute.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11648","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT281","PresenterBiography":null,"PresenterDisplayName":"Sarah Nissen","PresenterKey":"b9c6d2bd-f0bd-465d-8d52-b78e5681fe8d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT281. The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-03 Phase III clinical trials in progress,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),Topoisomerase II inhibitor,EGFR,EGFR TKI resistance,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>F. Cappuzzo<\/b><sup>1<\/sup>, E. Garon<sup>2<\/sup>, M.-J. Ahn<sup>3<\/sup>, S. Lu<sup>4<\/sup>, T. Kato<sup>5<\/sup>, E. Felip<sup>6<\/sup>, P. Cheema<sup>7<\/sup>, N. Girard<sup>8<\/sup>, M. Shamoun<sup>9<\/sup>, G. Wang<sup>9<\/sup>, B. Zhao<sup>9<\/sup>, R. Hui<sup>10<\/sup>; <br\/><sup>1<\/sup>Division of Medical Oncology 2, IRCCS \"Regina Elena\" National Cancer Institute, Rome, Italy, <sup>2<\/sup>Department of Medicine, Division of Hematology\/Oncology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, <sup>3<\/sup>Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of, <sup>4<\/sup>Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China, <sup>5<\/sup>Kanagawa Cancer Center, Yokohama, Japan, <sup>6<\/sup>Medical Oncology Department, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, <sup>7<\/sup>Division of Medical Oncology, William Osler Health System, University of Toronto, Brampton; and Faculty of Medicine, University of Toronto, Toronto, ON, Canada, <sup>8<\/sup>Institut Curie, Institut du Thorax Curie-Montsouris and Paris Saclay University, Université de Versailles Saint-Quentin-en-Yvelines, Versailles, Paris, France, <sup>9<\/sup>Merck & Co., Inc., Rahway, NJ, <sup>10<\/sup>Centre of Cancer Medicine, University of Hong Kong, Hong Kong; University of Sydney, Sydney, NSW, Australia","CSlideId":"","ControlKey":"c3225f13-7945-4bb8-9d79-7f23643985cf","ControlNumber":"10408","DisclosureBlock":"<b>&nbsp;F. Cappuzzo, <\/b> <br><b>Roche, AstraZeneca, BMS, Pfizer, Takeda, Lilly, Bayer, Amgen, Sanofi, Pharmamar, Novocure, Mirati, Galecto, OSE, ILLUMINA, Thermofisher and MSD<\/b> Other, Fees for membership of an advisory board or lectures. <br><b>E. Garon, <\/b> <br><b>Abbvie; Arcus; AstraZeneca, Atreca; BridgeBio; Bristol Myers Squibb; EMD Serono; Eli Lilly; Gilead; GlaxoSmithKline; Hookipa; LianBio<\/b> Other, Consultant and\/or Advisor. <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Merus; Novartis; Nuvalent; Personalis; Regeneron; Sanofi; Seagan; Sensei; Sumitomo; Summit; Synthekine; Xilio; Zymeworks<\/b> Other, Consultant and\/or Advisor. <br><b>ABL-Bio; Arrivent; AstraZeneca; Bristol Myers Squibb; Daiichi Sanko; Eli Lilly; EMD Serono; Genentech; Gilead; Iovance Biotherapeutics<\/b> Grant\/Contract. <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Mirati Therapeutics; Novartis; Prelude; Regeneron; Synthekine<\/b> Grant\/Contract. <br><b>Daiichi-Sankyo; Ipsen. Travel: A2 Bio; Novartis<\/b> Other, Sponsored Independent Medical Education. <br><b>M. Ahn, <\/b> <br><b>AstraZeneca, BMS, MSD, Lilly, Merck KGaA \/ Merck Serono \/ Merck Biopharma, ONO, Roche, Takeda, YUHAN, Amgen<\/b> Other, Honoraria. <br><b>AstraZeneca, BMS, ONO, Takeda, Lilly, Merck KGaA \/ Merck Serono \/ Merck Biopharma, MSD, Amgen, Novartis, Roche, YUHAN, Arcus, Pfizer, Daichi-Sankyo, Alpha pharmaceutical, Voronoi, Eutilex<\/b> Other, Consultant or Advisor. <br><b>S. Lu, <\/b> <br><b>AstraZeneca, Hutchison, BMS, Heng Rui, Beigene and Hansoh<\/b> Other, Received research support. <br><b>AstraZeneca, Roche, Hansoh, Hengrui Therapeutics<\/b> Other, Received speaker fees. <br><b>AstraZeneca, Pfizer, MediPharma, ZiaLab, Yuhan Corporation, Menarini, InventisBio Co. Ltd., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Simcere Zaiming Pharmaceutical Co., Ltd. and Roche<\/b> Other, An advisor and consultant role. <br><b>T. Kato, <\/b> <br><b>AstraZeneca, Chugai, Daiichi-Sankyo, Eli Lilly, Merck KGaA<\/b> Other, Honoraria. <br><b>AbbVie, Amgen, AstraZeneca, BeiGene Blueprint Chugai, Daiichi-Sankyo, Eli Lilly, Haihe, Merck Biopharma, MSD, Novartis, Pfizer, Regeneron Takeda, TurningPoint<\/b> Grant\/Contract, Grants for commissioned\/joint research. <br><b>E. Felip, <\/b> <br><b>AbbVie, AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Guardant Health, Janssen, Medscape, Merck KGaA,<\/b> Other, received personal fees as an advisor, consultant, and\/or speaker. <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Novartis, Pfizer, Roche, Takeda, Touchtime, BerGenBio, and Samsung<\/b> Other, received personal fees as an advisor, consultant, and\/or speaker. <br><b>Grífols<\/b> Other, independent member of the board. <br><b>P. Cheema, <\/b> <br><b>Amgen, BMS, AstraZeneca, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Novartis, Jansen, Roche, Pfizer, Sanofi<\/b> Other, Advisory boards and honorarium. <br><b>N. Girard, <\/b> <br><b>Abbvie, Amgen, AstraZeneca, Beigene, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Hoffmann-La Roche, Janssen, LeoPharma, Lilly,<\/b> Grant\/Contract. <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Novartis; Sivan<\/b> Grant\/Contract. <br><b>Abbvie, Amgen, AstraZeneca, Beigene, Bristol Myers Squibb, Daiichi-Sankyo, Gilead, Ipsen Hoffmann-La Roche, Janssen, LeoPharma<\/b> Other, Consultative services. <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Mirati; Novartis; Pfizer; Sanofi; Takeda<\/b> Other, Consultative services. <br><b>Hoffmann-La Roche<\/b> Other, Participation on a data safety monitoring board. <br><b>M. Shamoun, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>G. Wang, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>B. Zhao, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>R. Hui, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; AstraZeneca; Bristol Myers Squibb; Corvus; Eisai, Eli Lilly; Janssen; Novartis; Oncosec; Roche; and Seagen<\/b> Other, received study funding to the institution. <br><b>Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, Eli Lilly, Janssen, Merck Serono, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; Novartis; Oncosec; Pfizer; Roche<\/b> Other, received personal fees as an advisor and\/or speaker. <br><b>Seagen; Takeda; Zai Lab<\/b> Other, received personal fees as an advisor and\/or speaker.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11649","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT282","PresenterBiography":null,"PresenterDisplayName":"Federico Cappuzzo, MD","PresenterKey":"9c508724-a7f9-46c3-bc6a-73c780295c14","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT282. MK-2870-004: A phase 3 study of MK-2870 (SKB264) versus chemotherapy for previously treated advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) with <i>EGFR<\/i> mutations or other genomic alterations","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"MK-2870-004: A phase 3 study of MK-2870 (SKB264) versus chemotherapy for previously treated advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC) with <i>EGFR<\/i> mutations or other genomic alterations","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-03 Phase III clinical trials in progress,,"},{"Key":"Keywords","Value":"Pembrolizumab,Anti-PD-1,Antibody-drug conjugate (ADC),Topoisomerase II inhibitor,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"N. Frost<sup>1<\/sup>, R. Ghori<sup>2<\/sup>, A. Roy<sup>2<\/sup>, A. Nunes<sup>2<\/sup>, <b>J.-H. Yang<\/b><sup>3<\/sup>; <br\/><sup>1<\/sup>Department of Infectious Diseases and Respiratory Medicine, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany, <sup>2<\/sup>Merck & Co., Inc., Rahway, NJ, <sup>3<\/sup>National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan","CSlideId":"","ControlKey":"76cacd05-c740-43a7-918d-d90c47909a66","ControlNumber":"10429","DisclosureBlock":"<b>&nbsp;N. Frost, <\/b> <br><b>Roche<\/b> Grant\/Contract. <br><b>AbbVie, Amgen, AstraZeneca, BeiGene, Berlinchemie, Boehringer Ingelheim, Bristol Myers & Squibb, Lilly<\/b> Other, Consulting fees. <br><b>Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Merck KGaA\/Merck Serono, Novartis, Pfizer, Roche, Sanofi and Takeda<\/b> Other, Consulting fees. <br><b>Amgen, AstraZeneca, BMS, Janssen, Lilly and Takeda<\/b> Other, support for attending meetings and\/or travel. <br><b>German Respiratory Society (Deutsche Gesellschaft für Pneumologie) and the German Cancer Society (Deutsche Krebsgesellschaft; working group medical oncology)<\/b> Other, leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid. <br><b>R. Ghori, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>A. Roy, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>A. Nunes, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>J. Yang, <\/b> <br><b>AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda<\/b> Other, Honoraria. <br><b>Abbvie; Amgen; Amgen (Inst); AstraZeneca; AstraZeneca (Inst); Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology<\/b> Other, Consulting or Advisory Role. <br><b>Daiichi Sankyo; Daiichi Sankyo (Inst); G1 Therapeutics; GlaxoSmithKline (Inst); Hansoh; Incyte; Janssen (Inst); Lilly; Merck Serono; Merck Serono (Inst); MSD Oncology; MSD Oncology (Inst)<\/b> Other, Consulting or Advisory Role. <br><b>Novartis; Novartis (Inst); Ono Pharmaceutical; Pfizer; Takeda; Takeda (Inst); Yuhan<\/b> Other, Consulting or Advisory Role. <br><b>Pfizer; Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Other, Travel, Accommodations, Expenses.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11650","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT283","PresenterBiography":null,"PresenterDisplayName":"James Chih-Hsin Yang, MD;PhD","PresenterKey":"0c20c214-78cf-457e-bcd2-9fa5aa317341","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT283. Phase 3<b> <\/b>MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) &#8805;50%","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 3<b> <\/b>MK-2870-007 study: MK-2870 (SKB264) plus pembrolizumab vs pembrolizumab alone as first-line treatment for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score (TPS) &#8805;50%","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-03 Phase III clinical trials in progress,,"},{"Key":"Keywords","Value":"NSCLC,HER2,Tyrosine kinase inhibitor,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Y.-L. Wu<sup>1<\/sup>, M. Johnson<sup>2<\/sup>, R. Soo<sup>3<\/sup>, <b>N. Baktash<\/b><sup>4<\/sup>, D. Maier<sup>5<\/sup>, S. Eigenbrod-Giese<sup>6<\/sup>, T. Yoshida<sup>7<\/sup>; <br\/><sup>1<\/sup>Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, <sup>2<\/sup>Sarah Cannon Research Institute\/Tennessee Oncology, Nashville, TN, <sup>3<\/sup>National University Cancer Institute, Singapore, Singapore, <sup>4<\/sup>Boehringer Ingelheim (Canada) Ltd, Burlington, ON, Canada, <sup>5<\/sup>Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, <sup>6<\/sup>Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, <sup>7<\/sup>Department of Thoracic Oncology, National Cancer Center Hospital; Division of Molecular Pharmacology, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan","CSlideId":"","ControlKey":"70b58446-d005-4189-91ec-1b4e4d0413f4","ControlNumber":"10447","DisclosureBlock":"<b>&nbsp;Y. Wu, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Payment\/Honoraria. <br><b>Boehringer Ingelheim<\/b> Grant\/Contract, Other, Payment\/Honoraria. <br><b>Bristol-Myers Squibb<\/b> Grant\/Contract, Other, Payment\/Honoraria. <br><b>Hengrui<\/b> Grant\/Contract. <br><b>Roche<\/b> Grant\/Contract, Other, Payment\/Honoraria. <br><b>Beigen<\/b> Other, Payment\/Honoraria. <br><b>Eli Lilly and Company<\/b> Other, Payment\/Honoraria. <br><b>Merck Sharp & Dohme<\/b> Other, Payment\/Honoraria. <br><b>Pfizer<\/b> Other, Payment\/Honoraria. <br><b>Sanofi<\/b> Other, Payment\/Honoraria.<br><b>M. Johnson, <\/b> None.&nbsp;<br><b>R. Soo, <\/b> <br><b>Astra-Zeneca<\/b> Grant\/Contract, Payment\/Honoraria. <br><b>Boehringer Ingelheim<\/b> Grant\/Contract, Payment\/Honoraria. <br><b>Pfizer<\/b> Grant\/Contract, Other, Payment\/Honoraria. <br><b>Amgen<\/b> Other, Payment\/Honoraria. <br><b>Bayer<\/b> Other, Payment\/Honoraria. <br><b>BMS<\/b> Other, Payment\/Honoraria. <br><b>J INTS BIO<\/b> Other, Payment\/Honoraria. <br><b>Janssen<\/b> Other, Payment\/Honoraria. <br><b>Lily<\/b> Other, Payment\/Honoraria. <br><b>Merck<\/b> Other, Payment\/Honoraria. <br><b>Merck Serono<\/b> Other, Payment\/Honoraria. <br><b>Novartis<\/b> Other, Payment\/Honoraria. <br><b>Puma<\/b> Other, Payment\/Honoraria. <br><b>Roche<\/b> Other, Payment\/Honoraria. <br><b>Taiho<\/b> Other, Payment\/Honoraria. <br><b>Takeda<\/b> Other, Payment\/Honoraria. <br><b>Thermo Fisher<\/b> Other, Payment\/Honoraria. <br><b>Yuhan<\/b> Other, Payment\/Honoraria. <br><b>N. Baktash, <\/b> <br><b>Boehringer Ingelheim<\/b> Employment. <br><b>D. Maier, <\/b> <br><b>Boehringer Ingelheim<\/b> Employment. <br><b>S. Eigenbrod-Giese, <\/b> <br><b>Boehringer Ingelheim<\/b> Employment.<br><b>T. Yoshida, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11651","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"14","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT284","PresenterBiography":null,"PresenterDisplayName":"Navid Baktash, MSc","PresenterKey":"89f4cfb8-5dd0-4543-add5-e5acd40db55e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT284. A phase 3 randomized controlled trial of zongertinib (BI 1810631) compared with standard of care in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer harboring <i>HER2<\/i> tyrosine kinase domain mutations: Beamion LUNG-2","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 3 randomized controlled trial of zongertinib (BI 1810631) compared with standard of care in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer harboring <i>HER2<\/i> tyrosine kinase domain mutations: Beamion LUNG-2","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-02 Phase II clinical trials in progress,,"},{"Key":"Keywords","Value":"Tumor infiltrating lymphocytes,Melanoma\/skin cancers,Immuno-oncology,Adoptive cell therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. S. Thomas<\/b><sup>1<\/sup>, J. A. Chesney<sup>2<\/sup>, O. Hamid<sup>3<\/sup>, G. K. In<sup>4<\/sup>, A. N. Shoushtari<sup>5<\/sup>, Y. Samhouri<sup>6<\/sup>, P. Hari<sup>7<\/sup>, G. Ramsingh<sup>7<\/sup>, P. Prabhakar<sup>8<\/sup>, L. Mclaughlin<sup>7<\/sup>, A. Betof Warner<sup>9<\/sup>; <br\/><sup>1<\/sup>Orlando Health Cancer Institute, Orlando, FL, <sup>2<\/sup>UofL Health – Brown Cancer Center, Louisville, KY, <sup>3<\/sup>The Angeles Clinic and Research Institute, Cedars-Sinai, Los Angeles, CA, <sup>4<\/sup>Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, <sup>5<\/sup>Memorial Sloan Kettering Cancer Center, New York, NY, <sup>6<\/sup>Allegheny Health Network Cancer Institute, Pittsburgh, PA, <sup>7<\/sup>Obsidian Therapeutics, Inc., Cambridge, MA, <sup>8<\/sup>Obsidian Therapeutics, Inc, Cambridge, MA, <sup>9<\/sup>Stanford University School of Medicine, Stanford, CA","CSlideId":"","ControlKey":"0c3db0e0-15d3-4a51-a49a-037c568b4f1e","ControlNumber":"9885","DisclosureBlock":"<b>&nbsp;S. S. Thomas, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Other, Medical writing support. <br><b>J. A. Chesney, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Other, Medical writing support. <br><b>O. Hamid, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Other, Medical writing support. <br><b>Alkermes, Amgen, Bactonix, Beigene, Bioatla, BMS, Eisai, Roche Genentech, Georgiamune, GigaGen, Grit Bio, GSK, Idera, Immunocore, Incyte, Instilbio, IO Bio, Iovance, Janssen, KSQ, Merck, Moderna<\/b> Other, Consulting fees. <br><b>Novartis, Obsidian, Pfizer, Regeneron, Sanofi, Seattle Genetics, Tempus, Vial, Zelluna<\/b> Other, Consulting fees. <br><b>BMS, Immunocore, Novartis, Pfizer, Regeneron<\/b> Other, Speaker Bureau. <br><b>Alkermes, Amgen, Bactonix, Beigene, Bioatla, BMS, Eisai, Roche Genentech, Georgiamune, GigaGen, Grit Bio, GSK, Idera, Immunocore, Incyte, Instilbio, IO Bio, Iovance, Janssen, KSQ, Merck, Moderna<\/b> Travel. <br><b>Novartis, Obsidian, Pfizer, Regeneron, Sanofi, Seattle Genetics, Tempus, Vial, Zelluna<\/b> Travel. <br><b>Alkermes, Amgen, Bactonix, Beigene, Bioatla, BMS, Eisai, Roche Genentech, Georgiamune, GigaGen, Grit Bio, GSK, Idera, Immunocore, Incyte, Instilbio, IO Bio, Iovance, Janssen, KSQ, Merck, Moderna<\/b> Other, Data Safety Monitoring Board or Ad Board. <br><b>Novartis, Obsidian, Pfizer, Regeneron, Sanofi, Seattle Genetics, Tempus, Vial, Zelluna<\/b> Other, Data Safety Monitoring Board or Ad Board. <br><b>Bactonix<\/b> Stock. <br><b>Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, Cytomx, Exelixis, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Merck, Moderna, Merck Serono, Nextcure, Nvoartis, Pfizer, Regeneron<\/b> Other, Other financial\/non-financial interests. <br><b>Seattle Genetics, Torque, Zelluna<\/b> Other financial\/non-financial interests. <br><b>Obsidian Therapeutics, Inc.<\/b> Other, Medical writing support. <br><b>G. K. In, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Other, Medical writing support. <br><b>Regeneron<\/b> Grant\/Contract, Other, Advisory Board. <br><b>Array<\/b> Grant\/Contract. <br><b>Idera<\/b> Grant\/Contract. <br><b>Replimune<\/b> Fiduciary Officer, Grant\/Contract, Other, Advisory Board. <br><b>Xencor<\/b> Grant\/Contract. <br><b>InstilBio<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract, Other, Consulting, Advisory Board. <br><b>Checkmate Pharmaceuticals<\/b> Grant\/Contract. <br><b>Sanofi<\/b> Other, Consulting. <br><b>BMS, Merck, Castle<\/b> Other, Advisory Board. <br><b>A. N. Shoushtari, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Other, Medical writing support. <br><b>Bristol Myers Squibb, Novartis, Immunocore, Targovax, Pfizer, Alkermes, Checkmate Pharmaceuticals, Foghorn Therapeutics, Linnaeus Therapeutics, Iovance Biotherapeutics, Prelude Therapeutics<\/b> Grant\/Contract. <br><b>Bristol Myers Squibb, Novartis, Erasca<\/b> Other, Consulting. <br><b>Y. Samhouri, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Other, Medical writing support. <br><b>P. Hari, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock, Stock Option, Travel, Other, Medical writing support, other financial or non-financial interests. <br><b>G. Ramsingh, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock, Stock Option, Travel, Other, Medical writing support. <br><b>P. Prabhakar, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock, Stock Option, Travel, Other, Medical writing support, other financial or non-financial interests. <br><b>L. Mclaughlin, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Employment, Stock, Stock Option, Travel, Other, Medical writing support. <br><b>A. Betof Warner, <\/b> <br><b>Obsidian Therapeutics, Inc.<\/b> Other, Medical writing support. <br><b>Iovance Biotherapeutics<\/b> Travel, Other, Consulting, medical writing support. <br><b>Novartis, BluePath Solutions, Pfizer, InstilBio, Lyell Immunopharma, Bristol Myers Squibb, Immatics<\/b> Other, Consulting.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11652","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"15","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT285","PresenterBiography":null,"PresenterDisplayName":"Sajeve Thomas","PresenterKey":"37b7ee41-17f7-478a-84d3-ccef4e3f1d03","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT285. Trial in progress: A phase 1\/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Trial in progress: A phase 1\/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with immune checkpoint inhibitor (ICI)-resistant advanced or metastatic melanoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-03 Phase III clinical trials in progress,,"},{"Key":"Keywords","Value":"Tumor infiltrating lymphocytes,Adoptive immunotherapy,Neoantigens,Melanoma\/skin cancers,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>S. Thomas<\/b><sup>1<\/sup>, Y. K. Hong<sup>2<\/sup>, Y. Samhouri<sup>3<\/sup>, J. Larkin<sup>4<\/sup>, D. J. Olson<sup>5<\/sup>, G. K. In<sup>6<\/sup>, V. Atkinson<sup>7<\/sup>, P. Lammers<sup>8<\/sup>, A. J. S. Furness<sup>4<\/sup>, J. Martin-Liberal<sup>9<\/sup>, P. Terheyden<sup>10<\/sup>, A. S. Poklepovic<sup>11<\/sup>, R. H. Nguyen<sup>12<\/sup>, I. Peretz<sup>13<\/sup>, M. Butler<sup>14<\/sup>, A. Khattak<sup>15<\/sup>, L. Spain<sup>16<\/sup>, E. Gaughan<sup>17<\/sup>, M. Wilson<sup>18<\/sup>, J. W. Dubay<sup>19<\/sup>, A. Williams<sup>20<\/sup>, S. Goff<sup>21<\/sup>, G. C. Doolittle<sup>22<\/sup>, J. Chesney<sup>23<\/sup>, F. Finckenstein<sup>24<\/sup>, J. Chou<sup>24<\/sup>, X. Wu<sup>24<\/sup>, G. Sulur<sup>24<\/sup>, W. Shi<sup>24<\/sup>, J. Haanen<sup>25<\/sup>; <br\/><sup>1<\/sup>Orlando Health, Orlando, FL, <sup>2<\/sup>Cooper University Hospital, Camden, NJ, <sup>3<\/sup>Allegheny Health Network Cancer Institute, Pittsburgh, PA, <sup>4<\/sup>The Royal Marsden NHS Foundation Trust, London, United Kingdom, <sup>5<\/sup>University of Chicago, Chicago, IL, <sup>6<\/sup>University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, CA, <sup>7<\/sup>Greenslopes Private Hospital, Greenslopes, Queensland, Australia, <sup>8<\/sup>Baptist Cancer Center, Memphis, TN, <sup>9<\/sup>ICO L’Hospitalet – Hospital Duran i Reynals, Barcelona, Spain, <sup>10<\/sup>University of Lübeck, Lübeck, Germany, <sup>11<\/sup>Virginia Commonwealth University, Richmond, VA, <sup>12<\/sup>University of Illinois Hospital & Health Sciences System, Chicago, IL, <sup>13<\/sup>Rabin Medical Center – PPDS, Beilinson, Israel, <sup>14<\/sup>Princess Margaret Cancer Centre, Toronto, ON, Canada, <sup>15<\/sup>Fiona Stanley Hospital & Edith Cowan University, Murdoch & Joondalup, Australia, <sup>16<\/sup>Peter McCallum Cancer Centre, Melbourne, Australia, <sup>17<\/sup>University of Virginia, Charlottesville, VA, <sup>18<\/sup>St. Luke’s University Health Network, Division of Hematology Medical Oncology, Easton, PA, <sup>19<\/sup>University of Alabama at Birmingham, O’Neal Comprehensive Cancer Center, Birmingham, AL, <sup>20<\/sup>Sarah Cannon Research Institute SCRI, London, United Kingdom, <sup>21<\/sup>National Cancer Institute, Bethesda, MD, <sup>22<\/sup>University of Kansas Medical Center, Kansas City, KS, <sup>23<\/sup>UofL Health Brown Cancer Center, University of Louisville, Louisville, KY, <sup>24<\/sup>Iovance Biotherapeutics Inc, San Carlos, CA, <sup>25<\/sup>Netherlands Cancer Institute & Leiden University Medical Center, Amsterdam & Leiden, Netherlands","CSlideId":"","ControlKey":"800f4c81-72bc-42e1-af20-88b4e81881e7","ControlNumber":"9723","DisclosureBlock":"<b>&nbsp;S. Thomas, <\/b> <br><b>Bristol Myers Squibb<\/b> Travel, Other, Speakers Bureau, Consulting\/Advisory Role, Research Funding. <br><b>Merck<\/b> Travel, Other, Speakers Bureau, Consulting\/Advisory Role, Research Funding. <br><b>Pfizer<\/b> Travel, Other, Speakers Bureau, Consulting\/Advisory Role, Research Funding. <br><b>Ipsen<\/b> Travel, Other, Speakers Bureau, Consulting\/Advisory Role, Research Funding. <br><b>Amgen<\/b> Travel, Other, Speakers Bureau, Consulting\/Advisory Role, Research Funding. <br><b>Genentech<\/b> Travel, Other, Speakers Bureau, Consulting\/Advisory Role, Research Funding. <br><b>Foundation One<\/b> Travel, Other, Speakers Bureau, Consulting\/Advisory Role, Research Funding.<br><b>Y. K. Hong, <\/b> None..<br><b>Y. Samhouri, <\/b> None.&nbsp;<br><b>J. Larkin, <\/b> <br><b>iOnctura<\/b> Grant\/Contract, Other, Consulting\/Advisory Role. <br><b>Apple Tree<\/b> Other, Consulting\/Advisory Role. <br><b>Merck<\/b> Grant\/Contract, Other, Consulting\/Advisory Role, Speakers Bureau, Honoraria. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract, Other, Consulting\/Advisory Role, Research Funding, Speakers Bureau. <br><b>Eisai<\/b> Other, Consulting\/Advisory Role, Speaker Bureau, Honoraria. <br><b>Debiopharm<\/b> Other, Consulting\/Advisory Role. <br><b>Incyte<\/b> Other, Consulting\/Advisory Role, Honoraria. <br><b>Pfizer<\/b> Grant\/Contract, Other, Consulting\/Advisory Role, Speaker Bureau, Research Funding. <br><b>Novartis<\/b> Grant\/Contract, Other, Consulting\/Advisory Role, Honoraria, Research Funding, Speakers Bureau. <br><b>MSD<\/b> Other, Consulting\/Advisory Role. <br><b>Achilles<\/b> Grant\/Contract. <br><b>Nektar<\/b> Grant\/Contract, Other, Research Funding. <br><b>Roche<\/b> Grant\/Contract, Other, Research Funding, Speakers Bureau. <br><b>Immunocore<\/b> Grant\/Contract, Other, Reasearch Funding. <br><b>Aveo<\/b> Grant\/Contract, Other, Research Funding. <br><b>Pharmacyclics<\/b> Grant\/Contract, Other, Research Funding. <br><b>touchIME<\/b> Other, Honoraria. <br><b>touchEXPERTS<\/b> Other, Honoraria. <br><b>Royal College of Physicians<\/b> Other, Honoraria. <br><b>Cambridge Health Research<\/b> Other, Honoraria.<br><b>D. J. Olson, <\/b> None.&nbsp;<br><b>G. K. In, <\/b> <br><b>Regeneron<\/b> Other, Research Funding, Advisory\/Consulting. <br><b>Idera<\/b> Other, Research Funding. <br><b>Roche\/Genentech<\/b> Other, Research Funding. <br><b>Replimune<\/b> Other, Research Funding, Advisory\/Consulting. <br><b>Xencor<\/b> Other, Research Funding. <br><b>InstilBio<\/b> Other, Research Funding. <br><b>Pfizer<\/b> Other, Research Funding, Advisory\/Consulting. <br><b>Checkmate Pharmaceuticals<\/b> Other, Research Funding. <br><b>Bristol Mysers Squibb<\/b> Other, Research Funding. <br><b>Merck<\/b> Other, Research Funding, Advisory\/Consulting, Speaker. <br><b>Novartis<\/b> Other, Advisory\/Consulting. <br><b>Castle Biosciences<\/b> Other, Advisory\/Consulting. <br><b>Sanofi<\/b> Other, Advisory\/Consulting. <br><b>Array<\/b> Other, Advisory\/Consulting.<br><b>V. Atkinson, <\/b> None..<br><b>P. Lammers, <\/b> None..<br><b>A. J. S. Furness, <\/b> None.&nbsp;<br><b>J. Martin-Liberal, <\/b> <br><b>Astellas<\/b> Other, Lecture Fees. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract, Other, Lecture Fees, Advisory Fees. <br><b>MSD<\/b> Grant\/Contract, Other, Lecture. <br><b>Novartis<\/b> Grant\/Contract, Lecture Fees, Advisory Fees. <br><b>Pierre Fabre<\/b> Grant\/Contract, Lecture Fees, Advisory Fees. <br><b>Pfizer<\/b> Grant\/Contract, Other, Lecture Fees. <br><b>Roche<\/b> Grant\/Contract, Other, Lecture Fees, Advisory Fees. <br><b>Sanofi<\/b> Other, Lecture Fees, Advisory Fees. <br><b>Highlight Therapeutics<\/b> Other, Advisory Fees. <br><b>Ipsen<\/b> Grant\/Contract.<br><b>P. Terheyden, <\/b> None..<br><b>A. S. Poklepovic, <\/b> None.&nbsp;<br><b>R. H. Nguyen, <\/b> <br><b>Merck<\/b> Other, Speakers Bureau. <br><b>Novartis<\/b> Other, Consulting\/Advisory Role. <br><b>Exelixis<\/b> Other, Research Funding.<br><b>I. Peretz, <\/b> None..<br><b>M. Butler, <\/b> None.&nbsp;<br><b>A. Khattak, <\/b> <br><b>MSD<\/b> Other, Consultancy\/speakers bureau. <br><b>Bristol Myers Squibb<\/b> Other, Consultancy\/speakers bureau. <br><b>Merck Serono<\/b> Other, Consultancy\/speakers bureau. <br><b>Novartis<\/b> Other, Consultancy\/speakers bureau. <br><b>Pierre Fabre<\/b> Other, Consultancy\/speakers bureau. <br><b>Roche<\/b> Other, Consultancy\/speakers bureau. <br><b>L. Spain, <\/b> <br><b>Ipsen<\/b> Other, Advisory, Speakers fees. <br><b>Bristol Myers Squibb<\/b> Other, Speakers fees. <br><b>E. Gaughan, <\/b> <br><b>Iovance<\/b> Travel. <br><b>Regeneron<\/b> Travel, Other, Research Funding. <br><b>Bristol Myers Squibb<\/b> Other, Research Funding. <br><b>Merck<\/b> Other, Research Funding. <br><b>OncoBay<\/b> Other, Research Funding.<br><b>M. Wilson, <\/b> None..<br><b>J. W. Dubay, <\/b> None.&nbsp;<br><b>A. Williams, <\/b> <br><b>Ellipses Pharma<\/b> Other, Advisory Role.<br><b>S. Goff, <\/b> None..<br><b>G. C. Doolittle, <\/b> None..<br><b>J. Chesney, <\/b> None.&nbsp;<br><b>F. Finckenstein, <\/b> <br><b>Iovance Biotherapeutics Inc<\/b> Employment, Stock, Stock Option, Travel. <br><b>Bristol Myers Squibb<\/b> Patent, Other Intellectual Property. <br><b>J. Chou, <\/b> <br><b>Iovance Biotherapeutics Inc<\/b> Employment, Stock Option, Travel. <br><b>X. Wu, <\/b> <br><b>Iovance Biotherapeutics Inc<\/b> Stock, Stock Option, Travel. <br><b>G. Sulur, <\/b> <br><b>Iovance Biotherapeutics Inc<\/b> Employment, Stock, Stock Option, Travel. <br><b>W. Shi, <\/b> <br><b>Iovance Biotherapeutics Inc<\/b> Employment, Stock, Stock Option, Travel.<br><b>J. Haanen, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11653","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"16","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT286","PresenterBiography":null,"PresenterDisplayName":"Sajeve Thomas","PresenterKey":"37b7ee41-17f7-478a-84d3-ccef4e3f1d03","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT286. TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab vs pembrolizumab alone in treatment-naive unresectable or metastatic melanoma","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"TILVANCE-301, a phase 3 study of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab vs pembrolizumab alone in treatment-naive unresectable or metastatic melanoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-02 Phase II clinical trials in progress,,"},{"Key":"Keywords","Value":"Chemotherapy,Immune checkpoint blockade,Sarcoma\/soft-tissue malignancies,Immunomodulation,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>E. M. Gordon<\/b>, N. Omelchenko, S. Jeffrey, V. Kumar, N. S. Chawla, M. Seetharam, V. Chua, A. Moradkhani, D. Quon, S. Wong, S. Chawla; <br\/>Sarcoma Oncology Center, Santa Monica, CA","CSlideId":"","ControlKey":"6e6ae579-98d0-4c20-bc77-c1abd68ba769","ControlNumber":"10460","DisclosureBlock":"&nbsp;<b>E. M. Gordon, <\/b> None..<br><b>N. Omelchenko, <\/b> None..<br><b>S. Jeffrey, <\/b> None..<br><b>V. Kumar, <\/b> None..<br><b>N. S. Chawla, <\/b> None..<br><b>M. Seetharam, <\/b> None..<br><b>V. Chua, <\/b> None..<br><b>A. Moradkhani, <\/b> None..<br><b>D. Quon, <\/b> None..<br><b>S. Wong, <\/b> None..<br><b>S. Chawla, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11654","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"17","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT287","PresenterBiography":null,"PresenterDisplayName":"Erlinda Gordon, MD;MD (hc)","PresenterKey":"027d3309-bee9-4446-9d45-ba992d3f5d71","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT287. LINNOVATE: A Phase 1\/2 study of safety\/efficacy using <u>l<\/u>urbinectedin, combined with <u>i<\/u>pilimumab, and <u>n<\/u>ivolumab for advanced soft tissue sarcomas <i>(NCT05876715)<\/i>","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"LINNOVATE: A Phase 1\/2 study of safety\/efficacy using <u>l<\/u>urbinectedin, combined with <u>i<\/u>pilimumab, and <u>n<\/u>ivolumab for advanced soft tissue sarcomas <i>(NCT05876715)<\/i>","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-03 Phase III clinical trials in progress,,"},{"Key":"Keywords","Value":"Sarcoma\/soft-tissue malignancies,Targeted therapy,MDM2,p53,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"S. Schuetze<sup>1<\/sup>, G. Jayadeva<sup>2<\/sup>, <b>M. Santoro<\/b><sup>2<\/sup>; <br\/><sup>1<\/sup>University of Michigan Rogel Cancer Center, Ann Arbor, MI, <sup>2<\/sup>Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT","CSlideId":"","ControlKey":"1bcc379e-e1c5-4873-be5f-105aa7131aa6","ControlNumber":"10422","DisclosureBlock":"<b>&nbsp;S. Schuetze, <\/b> <br><b>Boehringer Ingelheim<\/b> Grant\/Contract. <br><b>Rain Oncology<\/b> Grant\/Contract. <br><b>UpToDate - Rare Sarcoma chapter<\/b> Other Intellectual Property. <br><b>G. Jayadeva, <\/b> <br><b>Boehringer Ingelheim<\/b> Employment. <br><b>M. Santoro, <\/b> <br><b>Boehringer Ingelheim<\/b> Employment.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11655","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"18","PosterboardNumber":"18","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT288","PresenterBiography":null,"PresenterDisplayName":"Michael Santoro, MS","PresenterKey":"b23e5b8f-704f-42c8-afc5-2ed25ec64bc8","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT288. Brightline-4: A phase 3 open-label, single-arm, multicenter study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-na&#239;ve or pretreated advanced dedifferentiated liposarcoma","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Brightline-4: A phase 3 open-label, single-arm, multicenter study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-na&#239;ve or pretreated advanced dedifferentiated liposarcoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-02 Phase II clinical trials in progress,,"},{"Key":"Keywords","Value":"Brain metastasis,HER2,Tucatinib,T-DM1,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>E. E. Dumbrava<\/b>, A. M. Kennon, R. K. Murthy, E. J. Montazari, H. Tawbi, J. Li, F. F. Lang, G. Sanchez, J. Wang, I. C. Glitza, B. J. O'Brien, T. Beckham, T. Swanson, M. C. Tom, U. M. Vu, T. T. Darko, T. Cai, K. Shah, F. Meric-Bernstam, J. Rodon; <br\/>UT MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"9af6fe16-9a91-49fe-9a88-44f4f48c2fbb","ControlNumber":"10500","DisclosureBlock":"<b>&nbsp;E. E. Dumbrava, <\/b> <br><b>Bayer HealthCare Pharmaceuticals Inc<\/b> Grant\/Contract. <br><b>Compugen Ltd<\/b> Grant\/Contract. <br><b>Gilead<\/b> Grant\/Contract. <br><b>Bellicum Pharmaceutical<\/b> Grant\/Contract. <br><b>PMV Pharma<\/b> Grant\/Contract, Other, Consulting\/Advisory. <br><b>Triumvira Immunologics<\/b> Grant\/Contract, Travel. <br><b>Seagen<\/b> Grant\/Contract. <br><b>Genentech<\/b> Grant\/Contract. <br><b>Mersana Therapeutics<\/b> Grant\/Contract, Consulting\/Advisory. <br><b>Boehringer Ingelheim<\/b> Grant\/Contract. <br><b>Dragonfly Therapeutics<\/b> Grant\/Contract. <br><b>A2A Pharmaceuticals<\/b> Grant\/Contract. <br><b>Orum Therapeutics<\/b> Other, Consulting\/Advisory. <br><b>Fate Therapeutics<\/b> Other, Consulting\/Advisory. <br><b>Summit Therapeutics<\/b> Other, Consulting\/Advisory. <br><b>Poseida<\/b> Grant\/Contract. <br><b>Rain Oncology<\/b> Grant\/Contract, Travel. <br><b>Aileron Therapeutics<\/b> Grant\/Contract.<br><b>A. M. Kennon, <\/b> None.&nbsp;<br><b>R. K. Murthy, <\/b> <br><b>Astra Zeneca<\/b> Other, Consulting\/Advisory. <br><b>Daiichi Sankyo<\/b> Other, Consulting\/Advisory. <br><b>Pfizer<\/b> Other, Consulting\/Advisory. <br><b>Seagen<\/b> Other, Consulting\/Advisory. <br><b>Novartis<\/b> Other, Consulting\/Advisory. <br><b>Sanofi<\/b> Other, Consulting\/Advisory. <br><b>Puma<\/b> Other, Consulting\/Advisory.<br><b>E. J. Montazari, <\/b> None.&nbsp;<br><b>H. Tawbi, <\/b> <br><b>Bristol Myers Squibb<\/b> Grant\/Contract, Other, Consulting\/Advisory. <br><b>Merck<\/b> Grant\/Contract, Other, Consulting\/Advisory. <br><b>Novartis<\/b> Grant\/Contract, Other, Consulting\/Advisory. <br><b>Medicenna<\/b> Other, Consulting\/Advisory. <br><b>Iovance<\/b> Other, Consulting\/Advisory. <br><b>Eisai<\/b> Other, Consulting\/Advisory. <br><b>Pfizer<\/b> Other, Consulting\/Advisory. <br><b>Karyopharm<\/b> Other, Consulting\/Advisory. <br><b>Dragonfly Therapeutics<\/b> Grant\/Contract. <br><b>GlaxoSmithKline<\/b> Grant\/Contract.<br><b>J. Li, <\/b> None..<br><b>F. F. Lang, <\/b> None..<br><b>G. Sanchez, <\/b> None..<br><b>J. Wang, <\/b> None..<br><b>I. C. Glitza, <\/b> None..<br><b>B. J. O'Brien, <\/b> None..<br><b>T. Beckham, <\/b> None..<br><b>T. Swanson, <\/b> None..<br><b>M. C. Tom, <\/b> None..<br><b>U. M. Vu, <\/b> None..<br><b>T. T. Darko, <\/b> None..<br><b>T. Cai, <\/b> None..<br><b>K. Shah, <\/b> None.&nbsp;<br><b>F. Meric-Bernstam, <\/b> <br><b>Astra Zeneca<\/b> Other, Consulting\/Advisory. <br><b>Black Diamond<\/b> Other, Consulting\/Advisory. <br><b>Genetech<\/b> Grant\/Contract. <br><b>Effector Therapeutics<\/b> Grant\/Contract. <br><b>Debiopharm International<\/b> Grant\/Contract. <br><b>Daiichi Sankyo Co. Ltd<\/b> Grant\/Contract. <br><b>CytomX Therapeutics Inc<\/b> Grant\/Contract. <br><b>Curis<\/b> Grant\/Contract. <br><b>Bayer Healthcare Pharmaceutical<\/b> Grant\/Contract. <br><b>Calithera Biosciences Inc<\/b> Grant\/Contract. <br><b>Seagen<\/b> Grant\/Contract. <br><b>Zentalis<\/b> Grant\/Contract, Other, Consulting\/Advisory. <br><b>Infinity Pharmaceuticals<\/b> Other, Consulting\/Advisory. <br><b>Incyte<\/b> Other, Consulting\/Advisory. <br><b>GT Apeiron<\/b> Other, Consulting\/Advisory. <br><b>Dava Oncology<\/b> Travel, Other, Consulting\/Advisory. <br><b>Zymeworks<\/b> Grant\/Contract, Other, Consulting\/Advisory. <br><b>Karyopharm<\/b> Other, Consulting\/Advisory. <br><b>J. Rodon, <\/b> <br><b>Symphogen<\/b> Grant\/Contract. <br><b>BioAlta<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Kelun-Biotech<\/b> Grant\/Contract. <br><b>GlaxoSmithKline<\/b> Grant\/Contract. <br><b>Hummingbird<\/b> Grant\/Contract. <br><b>Yingli<\/b> Grant\/Contract. <br><b>Bicycle Therapeutics<\/b> Grant\/Contract. <br><b>AadiBioscience<\/b> Grant\/Contract. <br><b>Loxo Oncology<\/b> Grant\/Contract, Travel. <br><b>Merus<\/b> Grant\/Contract. <br><b>ForeBio<\/b> Grant\/Contract. <br><b>Amgen<\/b> Consulting\/Advisory. <br><b>C4 Therapeutics<\/b> Grant\/Contract. <br><b>Linnaeus Therapeutics<\/b> Grant\/Contract. <br><b>Tango Therapeutic<\/b> Grant\/Contract. <br><b>Monterosa<\/b> Grant\/Contract, Other, Consulting\/Advisory. <br><b>Mirati<\/b> Grant\/Contract. <br><b>Beigene<\/b> Grant\/Contract. <br><b>Ellipses Pharma<\/b> Other, Consulting\/Advisory.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11656","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"19","PosterboardNumber":"19","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT289","PresenterBiography":null,"PresenterDisplayName":"Ecaterina Dumbrava, MD","PresenterKey":"b5a9d78d-5dd5-487f-99fa-e3aa7f8f8a38","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT289. A phase II study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in patients with HER2-positive metastatic solid tumors and metastases to brain (TUCATEMEB)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase II study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in patients with HER2-positive metastatic solid tumors and metastases to brain (TUCATEMEB)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-02 Phase II clinical trials in progress,,"},{"Key":"Keywords","Value":"Gastrointestinal stromal tumor,Breast cancer,Prostate cancer,Radiation therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>E. Mittra<\/b><sup>1<\/sup>, A. Iagaru<sup>2<\/sup>, A. Van der Veldt<sup>3<\/sup>, L. Aloj<sup>4<\/sup>, J. Wong<sup>5<\/sup>, L. Djaileb<sup>6<\/sup>, D. Pathak<sup>7<\/sup>, Y. Liu<sup>8<\/sup>, L. Solnes<sup>9<\/sup>; <br\/><sup>1<\/sup>Department of Diagnostic Radiology, Division of Molecular Imaging and Therapy, Oregon Health & Science University, Portland, OR, <sup>2<\/sup>Division of Nuclear Medicine and Molecular Imaging, Stanford University Medical Center, Stanford, CA, <sup>3<\/sup>Departments of Radiology & Nuclear Medicine and Medical Oncology, Erasmus Medical Center, Rotterdam, Netherlands, <sup>4<\/sup>Department of Radiology, University of Cambridge, Cambridge, United Kingdom, <sup>5<\/sup>Department of Radiation Oncology, City of Hope National Cancer Center, Duarte, CA, <sup>6<\/sup>Nuclear Medicine Department, LRB, INSERM, CHU Grenoble Alpes, Grenoble Alpes University, Grenoble, France, <sup>7<\/sup>Novartis Pharma AG, Basel, Switzerland, <sup>8<\/sup>Novartis Pharma Co, Beijing, China, <sup>9<\/sup>Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, John Hopkins University School of Medicine, Baltimore, MD","CSlideId":"","ControlKey":"d05153d2-8d2a-4438-8f54-2db75239dabe","ControlNumber":"9529","DisclosureBlock":"<b>&nbsp;E. Mittra, <\/b> <br><b>Curium<\/b> Grant\/Contract, Other, Consulting\/honoraria. <br><b>ITM<\/b> Grant\/Contract, Other, Consulting\/honoraria. <br><b>Clarity<\/b> Other, Consulting\/honoraria. <br><b>Lantheus<\/b> Other, Consulting\/honoraria. <br><b>Novartis<\/b> Grant\/Contract. <br><b>Nordic Nanovector<\/b> Grant\/Contract. <br><b>A. Iagaru, <\/b> <br><b>Alpha9Tx<\/b> Other, Scientific Advisory Board. <br><b>Clarity Pharmaceuticals<\/b> Other, Scientific Advisory Board. <br><b>GE Healthcare<\/b> Grant\/Contract, Other, Consulting. <br><b>Novartis<\/b> Grant\/Contract, Other, Consulting, study steering committee. <br><b>Progenics Pharmaceuticals<\/b> Other, Consulting. <br><b>Radionetics Oncology<\/b> Other, Scientific Advisory Board. <br><b>RayzeBio<\/b> Other, Consulting. <br><b>Telix<\/b> Other, Consulting. <br><b>A. Van der Veldt, <\/b> <br><b>BMS<\/b> Other, Consultancy. <br><b>MSD<\/b> Other, Consultancy. <br><b>Sanofi<\/b> Other, Consultancy. <br><b>Roche<\/b> Other, Consultancy. <br><b>Novartis<\/b> Other, Consultancy. <br><b>Eisai<\/b> Other, Consultancy. <br><b>Ipsen<\/b> Other, Consultancy. <br><b>Pfizer<\/b> Other, Consultancy. <br><b>Pierre Fabre<\/b> Other, Consultancy.<br><b>L. Aloj, <\/b> None.&nbsp;<br><b>J. Wong, <\/b> <br><b>Accuray<\/b> Grant\/Contract. <br><b>Varian<\/b> Grant\/Contract. <br><b>RefleXion<\/b> Grant\/Contract. <br><b>Telix Pharmaceuticals<\/b> Other, Consulting. <br><b>Blue Earth Diagnostics<\/b> Other, Consulting. <br><b>Janssen<\/b> Other, Industry trials. <br><b>Novartis<\/b> Other, Industry trials. <br><b>Imaginab<\/b> Other, Industry trials. <br><b>Fusion Pharmaceuticals<\/b> Other, Industry trials. <br><b>Precirix<\/b> Other, Industry trials.<br><b>L. Djaileb, <\/b> None.&nbsp;<br><b>D. Pathak, <\/b> <br><b>Novartis<\/b> Employment. <br><b>Y. Liu, <\/b> <br><b>Novartis<\/b> Employment. <br><b>L. Solnes, <\/b> <br><b>Novartis<\/b> Grant\/Contract. <br><b>Cellectar<\/b> Grant\/Contract. <br><b>Precision Molecular Imaging<\/b> Grant\/Contract. <br><b>Progenics Pharmaceuticals<\/b> Grant\/Contract. <br><b>Curium<\/b> Grant\/Contract. <br><b>Elsevier<\/b> Other, Royalties.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11657","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"20","PosterboardNumber":"20","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT290","PresenterBiography":null,"PresenterDisplayName":"Erik Mittra, MD;PhD","PresenterKey":"4742003b-52fb-408b-84c7-f434e3a6da60","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT290. Trial in progress: Evaluation of the safety, tolerability, whole-body distribution, radiation dosimetry and antitumor activity of <sup>177<\/sup>Lu-NeoB in patients with advanced solid tumors expressing gastrin-releasing peptide receptor (GRPR)","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Trial in progress: Evaluation of the safety, tolerability, whole-body distribution, radiation dosimetry and antitumor activity of <sup>177<\/sup>Lu-NeoB in patients with advanced solid tumors expressing gastrin-releasing peptide receptor (GRPR)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-02 Phase II clinical trials in progress,,"},{"Key":"Keywords","Value":"Lung cancer: non-small cell,Breast cancer,Gynecological cancers: ovarian,Genitourinary cancers: bladder,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"N. Yamamoto<sup>1<\/sup>, T. Doi<sup>2<\/sup>, M. R. Patel<sup>3<\/sup>, I. Garrido-Laguna<sup>4<\/sup>, S. Wu<sup>5<\/sup>, <b>S. Nishioka<\/b><sup>5<\/sup>, K. Nakajima<sup>5<\/sup>, B. A. Carneiro<sup>6<\/sup>; <br\/><sup>1<\/sup>National Cancer Center Hospital, Tokyo, Japan, <sup>2<\/sup>National Cancer Center Hospital East, Chiba, Japan, <sup>3<\/sup>Florida Cancer Specialists\/Sarah Cannon Research Institute, Sarasota, FL, <sup>4<\/sup>Huntsman Cancer Institute at University of Utah Health, Salt Lake City, UT, <sup>5<\/sup>Daiichi Sankyo, Inc., Basking Ridge, NJ, <sup>6<\/sup>Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, RI","CSlideId":"","ControlKey":"4c81762d-5595-45d8-8bb1-436d2621683c","ControlNumber":"10290","DisclosureBlock":"<b>&nbsp;N. Yamamoto, <\/b> <br><b>Astellas, Chugai, Eisai, Taiho, BMS, Pfizer, Novartis, Eli Lilly, AbbVie, Daiichi-Sankyo, Bayer, Boehringer Ingelheim, Kyowa Kirin, Takeda, ONO, Janssen Pharma, MSD, MERCK, GSK, Sumitomo Pharma<\/b> Other, Research grants as principal investigator (institution). <br><b>Chiome Bioscience, Otsuka, Carna Biosciences, Genmab, Shionogi, TORAY, KAKEN, AstraZeneca, Cmic, InventisBio, Rakuten Medical<\/b> Other, Research grants as principal investigator (institution). <br><b>Eisai, Takeda, Boehringer Ingelheim, Cmic, Chugai, MERCK, Healios<\/b> Other, Advisory role (personal). <br><b>ONO, Chugai, Daiichi-Sankyo, Eisai<\/b> Other, Honoraria as Speakers (personal). <br><b>T. Doi, <\/b> <br><b>AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, Eisai, IQVIA, Janssen<\/b> Research funding (institutional). <br><b>Lilly, Merck, Merck Sharp & Dohme, Novartis, Pfizer, SHIONOGI, Sumitomo Dainippon Pharma Oncology, Taiho<\/b> Other, Research funding (institutional). <br><b>A2 Health Care, AbbVie, Bayer, Chugai Pharma, KAKEN Pharma, KYOWA KIRIN, Noil Immune, Otsuka Pharma, PRA Health Science, Rakuten Medical, SHIONOGI, Sumitomo Dainippon, Taiho, and Takeda<\/b> Other, Consulting or Advisory Role. <br><b>AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Ono Pharma, and Rakuten Medical<\/b> Other, Honoraria. <br><b>AbbVie, Amgen, Astellas Pharma, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Janssen Pharma, Merck Sharp & Dohme, and Novartis<\/b> Other, Advisory Boards. <br><b>M. R. Patel, <\/b> <br><b>Accutar Biotech, Acerta Pharma, Adagene, ADC Therapeutics, Agenus, Aileron Therapeutics, Artios, Astellas Pharma, AstraZeneca, Bayer, Bicycle Therapeutics, BioNTech AG, BioTheryX<\/b> Research funding (institutional). <br><b>Black Diamond Therapeutics, Blueprint Medicines, Boehringer Ingelheim, Celgene, Ciclomed, Clovis Oncology, Compugen, Cullinan Oncology, Cyteir Therapeutics, Daiichi Sankyo<\/b> Research funding (institutional). <br><b>Erasca, Inc, Evelo Therapeutics, Genentech\/Roche, Gilead Sciences, GlaxoSmithKline, H3 Biomedicine, Hengrui Therapeutics, Hutchison MediPharma, IgM Biosciences<\/b> Research funding (institutional). <br><b>Immune-Onc Therapeutics, Immunitas, ImmunoGen, Jacobio Pharma, Janssen, Jazz Pharmaceuticals, KLUS Pharma, Kymab, Lilly, Loxo Oncology, LSK BioPartners, Lycera<\/b> Research funding (institutional). <br><b>MabSpace, MacroGenics, Merck, Millennium Pharmaceuticals, Mirati Therapeutics, Moderna Therapeutics, NGM Biopharmaceuticals, Novartis, Nurix<\/b> Research funding (institutional). <br><b>Olema, ORIC Pharmaceuticals, Pfizer, Pionyr, Prelude Therapeutics, PureTech Health, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Samumed<\/b> Research funding (institutional). <br><b>Seven and Eight Biopharmaceuticals, Silicon Therapeutics, Step Pharma, Syndax, Synthorx, Taiho Pharmaceutical, TeneoBio<\/b> Research funding (institutional). <br><b>Tesaro, TopAlliance BioSciences Inc, Treadwell Therapeutics, Vigeo, Xencor, and Zymeworks<\/b> Research funding (institutional). <br><b>ION Pharma<\/b> Other, Leadership. <br><b>Janssen Oncology<\/b> Other, Honoraria. <br><b>Olema Pharmaceuticals, Accutar, Incyte Corporation<\/b> Other, Consulting or Advisory Role. <br><b>I. Garrido-Laguna, <\/b> <br><b>Revolution Medicine, BridgeBio, Yingli, Repare, Sumitomo, Pfizer, BMS, MedImmune, Lilly, Novartis, and Bayer<\/b> Research grants as principal investigator (institution). <br><b>SOTIO, Jazz Pharmaceuticals, Kanaph, and OncXerna<\/b> Other, Honoraria. <br><b>S. Wu, <\/b> <br><b>Daiichi Sankyo, Inc.<\/b> Employment. <br><b>S. Nishioka, <\/b> <br><b>Daiichi Sankyo, Inc.<\/b> Employment. <br><b>K. Nakajima, <\/b> <br><b>Daiichi Sankyo, Inc.<\/b> Employment. <br><b>B. A. Carneiro, <\/b> <br><b>Actuate Therapeutics, AstraZeneca, AbbVie, Astellas, Agenus, Bayer, Dragonfly Therapeutics, Mink Therapeutics, Pfizer, Pyxis Oncology, Repare Therapeutics, Regeneron, and Seattle Genetics<\/b> Other, Support.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11658","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"21","PosterboardNumber":"21","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT291","PresenterBiography":null,"PresenterDisplayName":"Satoshi Nishioka, MS","PresenterKey":"8d187742-05fc-4432-ba18-aa8dc81374bd","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT291. A phase 1\/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 1\/2, first-in-human study of DS-3939a in patients with advanced solid tumors: A new DXd ADC targeting TA-MUC1","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-02 Phase II clinical trials in progress,,"},{"Key":"Keywords","Value":"Brain metastasis,Lenvatinib,Pembrolizumab,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Ecaterina  E.  Dumbrava<\/b><sup><\/sup>, Emma  J.  Montazari<sup><\/sup>, Uyen  M.  Vu<sup><\/sup>, Tiantian Cai<sup><\/sup>, Mehmet Altan<sup><\/sup>, Nuhad  K.  Ibrahim<sup><\/sup>, Debra  N.  Yeboa<sup><\/sup>, Jing Li<sup><\/sup>, Frederick  F.  Lang<sup><\/sup>, Gisela Sanchez<sup><\/sup>, Isabella  C.  Glitza<sup><\/sup>, Barbara  J.  O'Brien<sup><\/sup>, Rashmi  K.  Murthy<sup><\/sup>, Jianbo Wang<sup><\/sup>, Tanisha  T.  Darko<sup><\/sup>, Denisse Velazquez<sup><\/sup>, Komal Shah<sup><\/sup>, Funda Meric-Bernstam<sup><\/sup>, Hussein Tawbi<sup><\/sup>, Jordi Rodon<sup><\/sup><br><br\/>UT MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"50eb261f-af60-46bb-86e0-26d5220353b5","ControlNumber":"10860","DisclosureBlock":"<b>&nbsp;E. E. Dumbrava, <\/b> <br><b>Bayer HealthCare Pharmaceuticals Inc<\/b> Grant\/Contract. <br><b>Compugen Ltd<\/b> Grant\/Contract. <br><b>Gilead<\/b> Grant\/Contract. <br><b>Bellicum Pharmaceuticals<\/b> Grant\/Contract. <br><b>PMV Pharma<\/b> Grant\/Contract, Other, Advisory Board. <br><b>Triumvira Immunologics<\/b> Grant\/Contract, Travel. <br><b>Seagen Inc<\/b> Grant\/Contract. <br><b>Mersana Therapeutics<\/b> Grant\/Contract. <br><b>Genentech<\/b> Grant\/Contract. <br><b>Boehringer Ingelheim<\/b> Grant\/Contract. <br><b>Dragonfly Therapeutics<\/b> Grant\/Contract. <br><b>A2A Pharmaceuticals<\/b> Grant\/Contract. <br><b>Orum Therapeutics<\/b> Other, Advisory Board. <br><b>Summit Therapeutics<\/b> Other, Fate Therapeutics. <br><b>Poseida<\/b> Grant\/Contract. <br><b>Rain Oncology<\/b> Grant\/Contract, Travel.<br><b>E. J. Montazari, <\/b> None..<br><b>U. M. Vu, <\/b> None..<br><b>T. Cai, <\/b> None..<br><b>M. Altan, <\/b> None..<br><b>N. K. Ibrahim, <\/b> None..<br><b>D. N. Yeboa, <\/b> None..<br><b>J. Li, <\/b> None..<br><b>F. F. Lang, <\/b> None..<br><b>G. Sanchez, <\/b> None..<br><b>I. C. Glitza, <\/b> None..<br><b>B. J. O'Brien, <\/b> None.&nbsp;<br><b>R. K. Murthy, <\/b> <br><b>Astra Zeneca<\/b> Other, Consultant. <br><b>Daiichi sankyo<\/b> Other, Consultant. <br><b>Pfizer<\/b> Other, Consultant. <br><b>Seagen<\/b> Other, Consultant. <br><b>Novartis<\/b> Other, Consultant. <br><b>Sanofi<\/b> Other, Consultant. <br><b>Puma<\/b> Other, Consultant.<br><b>J. Wang, <\/b> None..<br><b>T. T. Darko, <\/b> None..<br><b>D. Velazquez, <\/b> None..<br><b>K. Shah, <\/b> None.&nbsp;<br><b>F. Meric-Bernstam, <\/b> <br><b>AstraZeneca<\/b> Other, Consulting\/Advisory Board. <br><b>Black Diamond<\/b> Other, Consulting\/Advisory Board. <br><b>Genentech<\/b> Grant\/Contract, Other. <br><b>eFFECTOR Therapeutics<\/b> Grant\/Contract, Other, Consulting\/Advisory Board. <br><b>Debiopharm International<\/b> Grant\/Contract. <br><b>Daiichi Sankyo Co. Ltd.,<\/b> Grant\/Contract. <br><b>CytomX Therapeutics Inc.<\/b> Grant\/Contract. <br><b>Curis Inc.<\/b> Grant\/Contract. <br><b>Bayer Healthcare Pharmaceutical<\/b> Grant\/Contract. <br><b>Calithera Biosciences Inc.,<\/b> Grant\/Contract. <br><b>Seagen<\/b> Grant\/Contract. <br><b>Zentallis<\/b> Grant\/Contract, Other, Consulting\/ Advisory Board. <br><b>Theratechnologies<\/b> Other, Consulting\/Advisory Board. <br><b>Zymeworks<\/b> Other, Consulting\/Advisory Board. <br><b>Hoffman-La Roche Ltd.<\/b> Other, Consulting\/Advisory Board. <br><b>Incyte<\/b> Other, Consulting\/Advisory Board. <br><b>Infinity Pharmaceuticals<\/b> Other, Consulting\/Advisory Board. <br><b>GT Apeiron<\/b> Other, Consulting\/Advisory Board. <br><b>Dava Oncology<\/b> Travel, Other, Consulting\/Advisory Board. <br><b>H. Tawbi, <\/b> <br><b>Bristol Myers Squibb<\/b> Other, Consulting\/ Advisory. <br><b>Merck<\/b> Grant\/Contract, Other, Consulting\/ Advisory. <br><b>Novartis<\/b> Grant\/Contract, Other, Consulting\/ Advisory. <br><b>Medicenna<\/b> Other, Consulting\/ Advisory. <br><b>Iovance<\/b> Other, Consulting\/ Advisory. <br><b>Eisai<\/b> Other, Consulting\/ Advisory. <br><b>Pfizer<\/b> Other, Consulting\/ Advisory. <br><b>Karyopharm<\/b> Other, Consulting\/ Advisory. <br><b>Dragonfly Therapeutics<\/b> Grant\/Contract. <br><b>GlaxoSmithKline<\/b> Grant\/Contract. <br><b>J. Rodon, <\/b> <br><b>Symphogen<\/b> Grant\/Contract. <br><b>BioAlta<\/b> Grant\/Contract. <br><b>Pfizer<\/b> Grant\/Contract. <br><b>Kelun-Biotech<\/b> Grant\/Contract. <br><b>GlaxoSmithKline<\/b> Grant\/Contract. <br><b>Hummingbird<\/b> Grant\/Contract. <br><b>Yingli<\/b> Grant\/Contract. <br><b>Bicycle Therapeutics<\/b> Grant\/Contract. <br><b>Loxo Oncology<\/b> Grant\/Contract, Travel. <br><b>Ellipses Pharma<\/b> Consulting\/Advisory. <br><b>Merus<\/b> Grant\/Contract. <br><b>ForeBio<\/b> Grant\/Contract. <br><b>AadiBioscience<\/b> Grant\/Contract, Other, Consulting\/Advisory. <br><b>Tango Therapeutics<\/b> Grant\/Contract. <br><b>C4 Therapeutics<\/b> Grant\/Contract. <br><b>Monterosa<\/b> Grant\/Contract, Other, Consulting\/Advisory. <br><b>Beigene<\/b> Grant\/Contract. <br><b>Linnaeus Therapeutics<\/b> Grant\/Contract. <br><b>Mirati<\/b> Grant\/Contract. <br><b>Amgen<\/b> Consulting\/Advisory.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11659","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"22","PosterboardNumber":"22","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT292","PresenterBiography":null,"PresenterDisplayName":"Ecaterina Dumbrava, MD","PresenterKey":"b5a9d78d-5dd5-487f-99fa-e3aa7f8f8a38","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT292. Phase II study of pembrolizumab in combination with lenvatinib in patients with triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and other tumor types and brain metastases","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase II study of pembrolizumab in combination with lenvatinib in patients with triple negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and other tumor types and brain metastases","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT01-03 Phase III clinical trials in progress,,"},{"Key":"Keywords","Value":"Head and neck squamous cell carcinoma,Breast cancer,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. Pace<\/b><sup>1<\/sup>, V. Castaldo<sup>1<\/sup>, M. G. Paggi<sup>1<\/sup>, E. Kyriacou<sup>2<\/sup>, C. Plomariti<sup>3<\/sup>, M. Rosinska<sup>4<\/sup>, T. Schmitt<sup>5<\/sup>, V. Leclercq<sup>5<\/sup>, eCAN WP5 research team; <br\/><sup>1<\/sup>IRCCS Regina Elena National Cancer Institute, Rome, Italy, <sup>2<\/sup>Cyprus University of technology, Limassol, Cyprus, <sup>3<\/sup>Aristotle University, Thessaloniki, Greece, <sup>4<\/sup>1IRCCS Regina Elena Cancer Institute, Rome, Italy, 2, Limassol, Cyprus, 3 Aristotle University of Thessaloniki, Greece, 4 Maria Sklodowska-Curie National Research Institute of Oncology, Warszawa, Poland, <sup>5<\/sup>Sciensano Cancer Center, Bruxelles, Belgium","CSlideId":"","ControlKey":"32ec280e-2c9a-4900-92fa-aa9eecabc590","ControlNumber":"9784","DisclosureBlock":"&nbsp;<b>A. Pace, <\/b> None..<br><b>V. Castaldo, <\/b> None..<br><b>M. G. Paggi, <\/b> None..<br><b>E. Kyriacou, <\/b> None..<br><b>C. Plomariti, <\/b> None..<br><b>M. Rosinska, <\/b> None..<br><b>T. Schmitt, <\/b> None..<br><b>V. Leclercq, <\/b> None.","End":"4\/9\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11660","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"23","PosterboardNumber":"23","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT293","PresenterBiography":"","PresenterDisplayName":"Andrea Pace, MD","PresenterKey":"ec76a772-19a0-4047-8405-39b76e51f898","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT293. eCAN Project : The EU Joint Action on strengthening eHealth including telemedicine and telemonitoring for cancer prevention and care","SearchResultFooter":"","SearchResultHeader":"Apr  9 2024  1:30PM","SessionId":"622","SessionOnDemand":"False","SessionTitle":"Phase II and Phase III Clinical Trials in Progress","ShowChatLink":"false","Start":"4\/9\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"eCAN Project : The EU Joint Action on strengthening eHealth including telemedicine and telemonitoring for cancer prevention and care","Topics":null,"cSlideId":""}]